Recurrent stroke prediction by applying a stroke polygenic risk score in the Japanese population

3

4 Naoki Kojima (MSc)¹, Masaru Koido (PhD)¹, Yunye He (PhD)¹, Yuka Shimmori (MSc)¹,
5 Tsuyoshi Hachiya (PhD)¹, BioBank Japan, Stéphanie Debette (MD, PhD)^{2,3}, Yoichiro
6 Kamatani (MD, PhD)¹

7

Laboratory of Complex Trait Genomics, Department of Computational Biology and
 Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo,
 Tokyo, Japan.

Bordeaux Population Health Research Center, University of Bordeaux, Inserm, UMR
 12 1219, Bordeaux, France.

- Department of Neurology, Institute for Neurodegenerative Diseases, CHU de Bordeaux,
 Bordeaux, France.
- 15
- 16 Short title: Recurrent stroke prediction by PRS

17

- 18 **Corresponding author:**
- 19 Yoichiro Kamatani¹
- 20 Address: 4-6-1 Shirokanedai, Minato-ku, Tokyo 108-8639 Japan
- 21 Email: <u>kamatani.yoichiro@edu.k.u-tokyo.ac.jp</u>
- 22

```
23 Total word count of the manuscript (including Title Page, Abstract, Text, References,
```

- 24 Tables, and Figures Legends): 6306
- 25

26

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

27 Abstract

28 Background

Recently, various polygenic risk score (PRS)-based methods were developed to improve stroke prediction. However, current PRSs (including cross-ancestry PRS) poorly predict recurrent stroke. Here, we aimed to determine whether the best PRS for Japanese individuals can also predict stroke recurrence in this population by extensively comparing the methods and maximizing the predictive performance for stroke onset.

34

35 Methods

We used data from the BioBank Japan (BBJ) 1st cohort (n=179,938) to derive and optimize the PRSs using a 10-fold cross-validation. We integrated the optimized PRSs for multiple traits, such as vascular risk factors and stroke subtypes to generate a single PRS using the meta-scoring approach (metaGRS). We used an independent BBJ 2nd cohort (n=41,929) as a test sample to evaluate the association of the metaGRS with stroke and recurrent stroke.

41

42 **Results**

We analyzed recurrent stroke cases (n=174) and non-recurrent stroke controls (n=1,153)43 among subjects within the BBJ 2nd cohort. After adjusting for known risk factors, metaGRS 44 45 was associated with stroke recurrence (adjusted OR per SD 1.18 [95% CI: 1.00-1.39, p=0.044]), although no significant correlation was observed with the published PRSs. We 46 47 administered three distinct tests to consider the potential index event bias; however, the outcomes derived from these examinations did not provide any significant indication of the 48 influence of index event bias. The high metaGRS group without a history of hypertension 49 50 had a higher risk of stroke recurrence than that of the low metaGRS group (adjusted OR 2.24 [95% CI: 1.07–4.66, p=0.032]). However, this association was weak in the hypertension 51

52 group (adjusted OR 1.21 [95% CI: 0.69–2.13, p=0.50]).

53

54 Conclusions

The metaGRS developed in a Japanese cohort predicted stroke recurrence in an independent cohort of patients. In particular, it predicted an increased risk of recurrence among stroke patients without hypertension. These findings provide clues for additional genetic risk stratification and help in developing personalized strategies for stroke recurrence prevention.

59

60 Keywords: recurrent stroke, stroke, polygenic risk score, LDpred2, risk factor, index event

61 bias, hypertension, metaGRS

62 Non-standard abbreviations and acronyms

- 63 PRS polygenic risk score
- 64 P+T pruning and thresholding
- 65 BBJ BioBank Japan
- 66 BBJ1 BBJ 1st cohort
- 67 BBJ2 BBJ 2nd cohort
- 68 ToMMo Tohoku Medical Megabank
- 69 AIS all ischemic stroke
- 70 IPW inverse probability weighting
- 71 LD linkage disequilibrium
- 72 GWAS genome-wide association study
- 73 PC principal component
- 74 IPW inverse probability weight
- 75 AUC area under the curve
- 76 LAS large artery stroke
- 77 SVS small vessel stroke
- 78 CES cardioembolic stroke
- 79 TIS transient ischemic attack
- 80 HWE Hardy-Weinberg equilibrium
- 81 WGS whole genome sequencing
- 82 MI myocardial infarction
- 83 SAP stable angina pectoris
- 84 AP unstable angina pectoris
- 85 AF atrial fibrillation
- 86 DM diabetes mellitus

87	SM	smoking
88	BMI	body mass index
89	HE	height
90	SBP	systolic blood pressure
91	DBP	diastolic blood pressure
92	TC	total cholesterol
93	TG	triglyceride
94	HDL	high-density lipoprotein
95	LDL	low-density lipoprotein
96		

97 Introduction

98

99 Stroke is a major cause of mortality in Japan, with 56,000 deaths reported in 2020.¹ The 100 conventional risk factors for stroke include hypertension, high waist-to-hip ratio, smoking, 101 cardiac causes, dyslipidemia, and diabetes mellitus.² In Japan, the stroke recurrence rate is up 102 to 30–50% during 5-10 years of follow-up after the first stroke.^{3,4} Accordingly, it will be 103 medically beneficial to stratify high-risk groups for recurrent stroke among those who have 104 experienced a stroke to potentially generate more intensive secondary prevention strategies 105 than current recommendations.

Genome-wide association studies (GWAS) have identified many disease-susceptibility 106 variants associated with complex traits.⁵ A polygenic risk score (PRS) is the weighted 107 108 summation of the individual genetic effects of these variants. Its weighting strategy varies 109 depending on the construction method; traditionally, only significant variants are used in 110 developing this score. The recently developed PRS methods involve non-significant variants 111 and updated effect weights and consider the linkage disequilibrium (LD) structure. The development of PRS methods has helped stratify high-risk groups for complex traits,⁶⁻¹¹ 112 including stroke.¹² 113

Polygenic risk scores developed using the 32 genome-wide significant ($p < 5.0 \times 10^{-8}$) variants 114 or 90 marginally associated ($p < 1.0 \times 10^{-5}$) variants (PRS₉₀) from the MEGASTROKE study¹² 115 are associated with stroke onset in subjects of European ancestry.^{12,13} The meta-scoring PRS 116 approach (metaGRS) includes 3.2 million variants by combining PRSs for stroke subtypes. 117 118 risk factors, and comorbidities by adjusting the effect weight via elastic-net logistic 119 regression; this approach has an improved predictive performance for stroke compared to that of PRS₉₀.¹⁴ MetaGRS can predict stroke incidence independent of environmental factors 120 121 and could help motivate individuals with high genetic risk to make lifestyle changes for 122 stroke prevention (although not yet implemented in clinical practice outside a research setting).¹⁵ The PRS shows reduced transferability between populations. Additionally, a PRS 123 developed using various variants derived from Japanese GWAS successfully predicted stroke 124 onset in the Japanese population.^{16,17} Most recently, the GIGASTROKE study proposed an 125 integrated PRS approach among PRSs derived from populations of multiple ancestries using 126 the metaGRS framework (iPGS), which showed a better predictive ability than the 127 MEGASTROKE European or East Asian PRS.¹⁸ However, the PRS did not successfully 128 predict stroke recurrence; for example, PRS₃₂ and iPGS did not significantly predict stroke 129 130 recurrence after adjusting for clinical comorbidities, with notably smaller effect sizes than for non-recurrent stroke.^{12,18} Furthermore, the potential effect of index event (also known as 131 "collider") bias that may distort the association of PRS was suspected.^{19,20} 132

The optimal method to improve the predictive accuracy of PRS depends on the populationand trait-specific genetic architecture.^{21–30} Therefore, we compared different PRS methods and determined whether the best PRS can predict the onset of recurrent stroke in a Japanese population.

137

139 Methods

140 The workflow of this study is shown in Figure 1. This article follows the TRIPOD 141 (Transparent reporting of a multivariable prediction model for individual prognosis or 142 diagnosis) reporting guidelines.

143

144 Study subjects and quality control

145 BioBank Japan (BBJ) involves physicians diagnosing all ischemic stroke (AIS) cases at the collaborating hospitals. BBJ was established in 2003 and recruited 267,000 patients from 12 146 medical institutions (66 hospitals) in two phases.^{31–33} The recruited patients had at least one 147 of the 51 primarily multifactorial (common) diseases, which accounted for 440,000 cases. 148 We used BBJ 1st cohort (BBJ1) data to derive PRSs and available independent BBJ 2nd 149 150 cohort (BBJ2) data to evaluate the performance of PRSs in predicting AIS and recurrent AIS. Recurrent AIS information was unavailable for the BBJ1 data. In BBJ2, any AIS cases 151 152 (n=1,470), AIS-free controls (n=40,459), recurrent AIS cases (n=174), and non-recurrent AIS 153 controls (n=1,153) were available. The mean duration from the first episode of AIS onset to recurrent AIS onset was 4.88 years. Detailed sample characteristics are listed in 154 Supplementary Methods and Table 1. 155

This study was approved by the ethics committee of the Institute of Medical Science, the University of Tokyo, Japan. Quality control, pre-phasing, and genotype imputation were conducted using PLINK(v2.0),^{34–37} Eagle (v2.4.1), and Minimac4 (v1.0.2), respectively. The detailed processes are presented in the Supplementary Methods.

160

161 Constructing PRSs for AIS

Unbiased PRSs were obtained by applying a 10-fold cross-validation to select the model and
 optimize the parameters.^{26,38} Briefly, BBJ1 samples were randomly split into ten equal-sized

subsamples. We retained one subsample for validation and the others for training. We repeated this process 10 times, with each of the ten subsamples used exactly once for validation. A GWAS was conducted on the training set in each iteration, adjusted for age, sex, and the first 10 principal components (PCs) via Firth logistic regression using PLINK (v.2.0).³⁴

We obtained the weights of variants for PRS from the GWAS summary statistics of the 169 training set using five PRS methods—P+T (PLINK (v.1.9)³⁵ for clumping), LDpred2,³⁹ 170 Lassosum2,⁴⁰ (LDpred2 and Lassosum2 by bigsnpr package (v.1.7.2) in R (v.3.5.0)), PRS-CS 171 (v.1.0.0),⁴¹ and PRS-CSx (v.1.0.0).⁴² The PRS-CSx integrated BBJ1 with the European 172 stroke GWAS summary statistics (MEGASTROKE; the largest study available at this study 173 design)⁴³ by learning an optimal linear combination. We used combinations of parameters for 174 175 P+T (1,224 parameters), LDpred2 (126 parameters), Lassosum2 (200 parameters), PRS-CS (9 parameters), and PRS-CSx (9 parameters), as described in the Supplementary Methods. 176

Subsequently, the PRSs for the validation sample were calculated using the weights obtained from the training samples. The accuracy for predicting AIS cases was evaluated from Nagelkerke's R^2 (simply " R^2 " from this point onwards)^{29,44} after adjusting for age, sex, and the first 10 PCs. We calculated the mean R^2 over 10 cross-validation results for each method with each parameter after a 10-fold cross-validation. We chose the method and parameters that maximized incremental R^2 (PRS_{AIS}) among these PRSs.

We further integrated the PRS_{AIS} with PRSs of vascular risk factors, such as stroke subtypes and comorbid diseases presence, using the elastic net framework to construct a metaGRS using the glmnet package (v.4.1.3) in R (v.4.1.0). Nine binary traits and eight quantitative traits of vascular risk factors reported in a previous study¹⁴ are described in the Supplementary Methods. Binary traits were determined by conducting GWAS and attempting to obtain unbiased weights using cross-validations. The effect weights from the derivation sample every 17 traits were calculated using PRS-CS-auto since it did not require an
independent validation sample set for parameter optimization and performed well for various
traits.^{21,26,39,41,45} Subsequently, we used a validation sample to calculate the weight of AIS
and the 17-trait PRSs to predict AIS using elastic-net logistic regression. We conducted a 10fold cross-validation and used the mean weight for testing.
We used PLINK (v2.0)³⁴ to calculate the individual PRS by aggregating the effect estimates
multiplied by each imputed dosage into a single score per person.

196

197 Risk factors

The following seven risk factors that were previously utilized as covariates¹² were used as covariates for testing: hypertension (systolic blood pressure>140 mmHg, diastolic blood pressure>90 mmHg, or hypertension history), hyperlipidemia, diabetes (all types), smoking (current smoker), vascular disease (myocardial infarction, peripheral artery disease, stable angina pectoris, and unstable angina pectoris), congestive heart failure, and atrial fibrillation (including atrial flutter). A sample was considered to have a risk factor status if it had that status at enrollment or from historical records (Tables 1 and S1).

205

206 Assessment of the association of PRS with AIS and AIS recurrence

We used a single selected method with optimized parameters and calculated the metaGRS in independent testing sample sets. We used a logistic regression model to assess the association of the PRS using the two case-control settings for AIS (any-AIS versus AIS-free controls) and AIS recurrence (recurrent AIS versus non-recurrent AIS). We also applied two other combinations of case-controls: recurrent AIS versus AIS-free controls and non-recurrent AIS versus AIS-free controls (Figure 1). Furthermore, we examined additional PRS contributions of the seven risk factors to predictive accuracy and discriminative performance using the

values of R^2 and area under the curve (AUC), according to our previous studies.^{14,46}

Additionally, we evaluated the performance of the following PRSs derived from other milestone studies for stroke prediction: 32 genome-wide significant variants (for any stroke, ischemic stroke, or ischemic stroke subtypes) from the MEGASTROKE cross-ancestry study of 524,354 individuals (PRS₃₂),⁴³ 89 genome-wide significant variants of 1,614,080 multipopulation individuals (PRS₈₉), and 6,010,730 variants of the East Asian PRS developed from 9,809 individuals (iPGS_{EAS}),¹⁸ both from the GIGASTROKE study. The PRS calculation process is described in the Supplementary Methods.

222

223 Considering potential index event bias

An index event bias may be induced when the samples are only selected from cases.⁴⁷ We 224 225 evaluated the extent to which the index event bias affected our results since we used caseonly samples in this study. The association of PRSs with recurrent AIS was evaluated after 226 adjusting for seven risk factors, in addition to age, sex, and the first 10 PCs. Adjusting for 227 228 such confounding bias will not be enough to eliminate bias for a recurrence association study.⁴⁸ Therefore, we sought to mitigate a potential index event bias by applying three 229 distinct methodologies.^{48,49} First, we utilized linear and logistic regression models to assess 230 231 the relationships between metaGRS and covariates within the any-AIS case (n=1,327) and 232 AIS-free control groups (n=40,459). Initially, we did not adjust for age, sex, the seven risk 233 factors, or the first 10 PCs. Subsequently, we observed the distributions of covariate values 234 across the metaGRS quintiles. We performed statistical tests to detect heterogeneity in the 235 estimates between the prevalent case and control groups, following the methodology of a prior study.^{19,50} Second, we refined our analysis by adjusting for associations between 236 metaGRS and AIS recurrence while considering the differential effects of covariates, 237 according to a previous method.¹⁹ Finally, we applied the inverse probability weighted (IPW) 238

approach⁴⁷ to comprehensively account for index event bias. Collectively, these analytical
approaches were adopted to enhance the validity of our findings.

241

242 Association of metaGRS and AIS recurrence in patients with/without hypertension

Logistic regression was conducted in subgroups with and without hypertension and metaGRS tertiles among recurrent AIS cases (with hypertension n=107, without hypertension n=67) and non-recurrent AIS controls (with hypertension n=731, without hypertension n=422) to assess the relationship between the PRS and the risk of AIS recurrence. The low metaGRS tertile was set as the reference group and adjusted for age, sex, and the first 10 PCs.

248

249 Statistical analysis

250 The mean with standard deviation (SD) or proportion of factors was reported for the baseline characteristics of testing samples. The incremental value (R^2 or AUC) was estimated from 251 the differences between patients with and without PRSs of the fitted values of age, sex, first 252 10 PCs, and seven risk factors^{48,57,58} and calculated as the 95% confidence interval. The 253 pROC package (v.1.18.0) in R was used to determine the discriminative ability of the AUC. 254 The IPW package (v.1.2) in R was used for the IPW approach. R (v. 3.5.0) was used to 255 perform logistic regression to calculate R^2 , Pearson's correlation coefficient, and linear 256 257 regression. All statistical tests were two-sided. The significance level was set at p = 0.05.

- 258
- 259

260 Results

261

262 **Derivation of effect weight**

The imputed genotype data of 17,621 AIS cases and 162,317 controls without an AIS diagnosis were used for 9,622,629 autosomal variants after implementing quality control of the BBJ1 dataset (Tables S2-S4).

We conducted a 10-fold cross-validation to adjust the parameters and select the best PRS associated with AIS. We performed GWAS 10 times on 90% of the randomly selected BBJ1 dataset (training data). We successfully detected previously reported^{43,51} signals in each dataset ($p < 5 \times 10^{-8}$), including *SH3PXD2A*, *CCDC63* (eight times), *CUX2*, and *LINC02356* (every time) (Figure S1, Table S5).

271 We confirmed some expected characteristics of each PRS method (such as low accuracy) 272 using only genome-wide significant variants (Tables S6-10 and Supplementary Notes). The mean incremental R^2 values of each scoring method with the best-performed parameters 273 274 were 0.0038 (95% CI: 0.0030-0.0046), 0.00443 (95% CI: 0.0035-0.0054), 0.0039 (95% CI: 275 0.0030-0.0048), 0.00441 (95% CI: 0.0036-0.0053), and 0.0037 (95% CI: 0.0031-0.0042) for P+T, LDpred2, Lassosum2, PRS-CS, and PRS-CSx, respectively (Table 2). We chose 276 LDpred2 with the parameter set of ρ -value = 0.0056, a heritability-value = $1.0 \times h_{LDSC}^2$ 277 where h_{LDSC}^2 is the heritability estimate from the constrained LD score regression⁵², and a 278 279 no-sparse model for subsequent analyses, since it showed the best mean incremental R^2 value 280 among the five methods.

We observed an average number of nonzero weights for 8.4 traits after computing the metaGRS via elastic net regularization 10 times (10-fold). The metaGRS weight of AIS was highest (mean=0.123, SD=0.026), followed by diastolic blood pressure (mean=0.039, SD=0.039), atrial fibrillation (mean=0.023, SD=0.024), and myocardial infarction (mean=0.018, SD=0.025) (Figure S2 and Table S11). Only the triglyceride weights were zero
at all 10 measurements among the 18 traits included in the metaGRS calculation. The number
of variants used for metaGRS was 1,014,026; a total of 1,011,847 variants (99.8%) remained
after matching with the BBJ2 dataset.

289

290 Association of metaGRS with AIS cases and recurrent AIS

We used the imputed genotype data of 1,470 AIS cases and 40,459 controls without a diagnosis of AIS for 59,387,070 variants from the BBJ2 dataset to test the association of metaGRS with AIS and AIS recurrence. The AIS case-only sample of the BBJ2 was used to analyze AIS recurrence. Table 1 presents the characteristics of the test samples.

MetaGRS was associated with AIS diagnosis after adjusting for age, sex, first 10 PCs, and seven risk factors (adjusted OR, 1.21 [95% CI: 1.15–1.27, p= 2.89×10^{-12}]), as previously reported.^{14,18} MetaGRS was also associated with AIS recurrence compared with recurrencefree AIS (adjusted OR 1.18 [95% CI: 1.00–1.39, p=0.044]; Table 3 and Figure S3). MetaGRS showed stronger association when comparing recurrent AIS with AIS-free controls (adjusted OR 1.37 [95% CI: 1.18–1.59, p= 5.35×10^{-5}]; Table S12).

The contribution of the metaGRS and traditional risk factors showed an AIS prediction accuracy with an R^2 value of 0.06 and an AUC of 0.689 after constructing the baseline model using age, sex, the first 10 PCs, and seven risk factors. The incremental AUCs were 0.0087 and 0.0123 for AIS and AIS recurrence, respectively when metaGRS was added to the baseline model (Table 3). In our dataset, clinical risk factors (including hypertension) were related to AIS diagnosis but were insignificantly associated with AIS recurrence (Table S1).

We assessed the prediction performance of previously developed PRSs for AIS and AISrecurrence in our dataset. After matching with the BBJ2 dataset (Supplementary Methods),

309 27, 84, and 5,756,652 variants remained in PRS₃₂, PRS₈₉, and iPGS, respectively. We

confirmed their association with AIS diagnosis; adjusted ORs were 1.11 [95% CI: 1.06–1.17, $p=4.23\times10^{-5}$], 1.08 [95% CI: 1.03–1.14, $p=2.96\times10^{-3}$], and 1.26 [95% CI: 1.20–1.33, $p=1.24\times10^{-17}$] for PRS₃₂, PRS₈₉, and iPGS, respectively (Table 3, Figure S3); however, a significant association was not observed between PRSs and AIS recurrence (p-values of 0.41, 0.054, and 0.37, respectively; Table 3 and Figure S3). Our Japanese optimized metaGRS was the only PRS significantly associated with AIS recurrence in this study.

316

317 Analyzing for potential index event bias

We observed the values of covariates at the AIS-free control group and any-AIS case group in each quintile. We did not find any significant heterogeneous relationships between the covariates and the metaGRS in terms of regression estimates in the prevalent case and control samples (p>0.05, Table S13).

We used three different variable models—i) age and sex; ii) age, sex, and seven risk factors; and iii) age, sex, the first 10 PCs, and seven risk factors—to determine the association between metaGRS and recurrent AIS; none of these confounders significantly influenced our results (Figure S4).

We compared the association results of IPW adjusted (accounting for index event bias) with those of non-adjusted IPW (accounting for confounding bias). The results remained almost unchanged, but the 95% confidence intervals overlapped (Figure S5). A comparison of the three distinct models did not indicate an effect of index event bias.

330

331 Association of metaGRS and AIS recurrence in patients with/without hypertension

We divided the test sample into subgroups according to the presence or absence of a history of hypertension and evaluated the risk effect of the metaGRS tertile. The high metaGRS group without a history of hypertension showed a higher risk effect for AIS recurrence

335	compared to the low metaGRS group (OR of the high metaGRS group compared to that of
336	the low metaGRS group was 2.24 [95% CI: 1.07–4.66, p=0.032], Figure 2 and Table S14).
337	However, no significant association was observed between the metaGRS and AIS recurrence
338	in the group with a history of hypertension (the OR of the high metaGRS group compared to
339	that of the low metaGRS group was 1.21 [95% CI: 0.69–2.13, p=0.50] (Figure 2 and Table
340	S14).
341	

343 **Discussion**

We successfully examined the association between recurrent AIS and our best model PRS 344 (metaGRS using LDpred2); the adjusted OR was 1.18 for each unit of SD increase in PRS. 345 346 Our metaGRS showed stronger (adjusted OR per SD=1.37) association when comparing recurrent AIS with AIS-free controls. Furthermore, a high PRS was associated with AIS 347 recurrence particularly in groups without a history of hypertension (OR of the top vs. bottom 348 349 metaGRS tertile=2.24). These results are consistent with the result of a previous study wherein the stroke prediction accuracy of the PRS was high in the group with low 350 CHA2DS2-VASc scores.¹² These results indicate the utility of the PRS in developing more 351 352 precise strategies to prevent AIS recurrence in individuals with a high PRS who do not have high profiles based on clinical risk factors. 353

354 We attempted to mitigate potential index event bias since our purpose was to specifically determine the efficacy of PRS among AIS patients. It is difficult to predict and provide an 355 accurate assessment of recurrent AIS based on genetic predisposition owing to the possible 356 357 effect of index event bias leading to a distorted association in studies on recurrent stroke.^{19,20,53} This study found no evidence of heterogeneous associations between covariates 358 and the metaGRS; we did not find any evidence of a solid collider bias of known variables. 359 By applying IPW, we confirmed that our results support the association between metaGRS 360 361 and recurrent AIS.

There are three putative reasons our metaGRS could predict AIS recurrence. First, the metaGRS algorithm combines the genetic profiles of related traits and slightly improves the performance, reaching the level of significance. Second, the performances of PRS-CS (incremental R²=0.00441) and LDpred2 (incremental R²=0.00443) in our validation analysis were better than those of other traditional PRS methods, such as P+T (incremental R²=0.0038). This demonstrated the importance of using shrinkage estimation methods that

368 consider LD to predict AIS and AIS recurrence. Third, we restricted to use only single369 matched ancestry throughout.

370 Nevertheless, our study had several limitations. First, the sample size for recurrent AIS needs 371 to be increased (n=174 at testing), even in the largest hospital-based biobank in Japan. Compared to our metaGRS, iPGS constructed in GIGASTROKE showed a stronger 372 association for AIS and weaker association for AIS recurrence. Although potential 373 374 discrepancies exist, both PRSs (metaGRS and iPGS) exhibit the same direction of effects and 375 have overlapping confidence intervals (Table 3, Figure S3). Second, despite using as many 376 covariates (age, sex, the first 10 PCs, and seven risk factors (hypertension, hyperlipidemia, 377 diabetes mellitus, smoking, vascular disease, congestive heart failure, and atrial fibrillation)) as possible based on a previous study,¹² other confounders might have affected our results. 378 379 Finally, there may have been an index event bias that was not fully detected by each method 380 that we implemented; however this risk was minimized using multiple approaches. Further 381 studies using different sample sets (including other ancestry groups) are warranted to confirm 382 the prediction of recurrent stroke using the PRS.

383

In conclusion, our study indicated that PRS can be applied to predict AIS recurrence in addition to traditional clinical risk factors. This shows the potential utility of PRS in population-based screening and in the clinical setting. Overall, our results indicate that stratifying high-risk groups for recurrent stroke among those who have experienced a stroke could be medically beneficial and help in developing personalized strategies for recurrence prevention. Our results suggest that it might be particularly useful in patients with AIS without hypertension, although this requires confirmation in independent datasets.

	392	Acknowledgment	S
--	-----	----------------	---

393	We want to acknowledge all the participants and investigators of BioBank Japan.
394	Supercomputing resources were provided by the Human Genome Center, Institute of Medical
395	Science, and the University of Tokyo (http://sc.hgc.jp/shirokane.html). The ToMMo
396	summary statistics were derived from jMorp (https://jmorp.megabank.tohoku.ac.jp/gwas-
397	studies/TGA000007). The MEGASTROKE project received funding from sources specified
398	at https://www.megastroke.org/acknowledgements.html

399

400 Data availability

- 401 The weights of metaGRS derived in this study will be publicly available after acceptance.
- 402 Genotype datasets were deposited in the National Bioscience Database Center Human
- 403 Database (BBJ1, Research ID: hum0014; BBJ2, Research ID: hum0311).

404

405 **Source of Funding**

406 This research was supported by the Ministry of Education, Culture, Sports, Sciences and407 Technology (MEXT) of the Japanese government and the Japan Agency for Medical

408 Research and Development (AMED) under grant nos. JP18km0605001/ JP23tm0624002 (the

409 BioBank Japan project), JP223fa627011 (Y.K.), and JP23tm0524003 (Y.K.).

410

411 **Disclosures**

412 Y.K. holds stock of StaGen Co, Ltd.

- 414 Supplementary Material
- 415 Supplementary Methods
- 416 Supplementary Notes

- 417 Tables S1–S15
- 418 Figures S1–S5
- 419
- 420 References

- 422 1. Ministry of Health, L. and W. Vital Statistics of Japan,
 423 https://www.mhlw.go.jp/toukei/saikin/hw/jinkou/kakutei20/index.html. (2020).
- 424 2. O'Donnell, M. J. *et al.* Global and regional effects of potentially modifiable risk
 425 factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control
 426 study. *The Lancet* **388**, 761–775 (2016).
- 427 3. Hata, J. *et al.* Ten year recurrence after first ever stroke in a Japanese community: The
 428 Hisayama study. *J Neurol Neurosurg Psychiatry* 76, 368–372 (2005).
- 429 4. Takashima, N. *et al.* Long-term survival after stroke in 1.4 million japanese
 430 population: Shiga stroke and heart attack registry. *J Stroke* 22, 336–344 (2020).
- 431 5. MacArthur, J. *et al.* The new NHGRI-EBI Catalog of published genome-wide 432 association studies (GWAS Catalog). *Nucleic Acids Res* **45**, D896–D901 (2017).
- 433 6. Torkamani, A., Wineinger, N. E. & Topol, E. J. The personal and clinical utility of
 434 polygenic risk scores. *Nat Rev Genet* 19, 581–590 (2018).
- Khera, A. v. *et al.* Whole-Genome Sequencing to Characterize Monogenic and
 Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial
 Infarction. *Circulation* 139, 1593–1602 (2019).
- 438 8. Konuma, T. & Okada, Y. Statistical genetics and polygenic risk score for precision
 439 medicine. *Inflamm Regen* 41, (2021).
- 440 9. Levin, M. G. & Rader, D. J. Polygenic Risk Scores and Coronary Artery Disease.
 441 *Circulation* 637–640 (2020) doi:10.1161/CIRCULATIONAHA.119.044770.
- 442 10. Plagnol, V. Polygenic score development in the era of large-scale biobanks. *Cell*443 *Genomics* 2, 100088 (2022).
- Khera, A. v. *et al.* Genome-wide polygenic scores for common diseases identify
 individuals with risk equivalent to monogenic mutations. *Nature Genetics* vol. 50
 1219–1224 Preprint at https://doi.org/10.1038/s41588-018-0183-z (2018).
- 447 12. Marston NA *et al.* Clinical Application of A Novel Genetic Risk Score Predicts
 448 Ischemic Stroke in Patients With Cardiometabolic Disease. *Circulation. 2021 Feb*449 2;143(5):470-478. doi: 10.1161/CIRCULATIONAHA.120.051927. Epub 2020 Nov 13.
 450 PMID: 33185476; PMCID: PMC7856243. (2020).
- 451 13. Rutten-Jacobs, L. C. A. *et al.* Genetic risk, incident stroke, and the benefits of adhering
 452 to a healthy lifestyle: Cohort study of 306 473 UK Biobank participants. *BMJ (Online)*453 363, 1–8 (2018).
- 454 14. Abraham, G. *et al.* Genomic risk score offers predictive performance comparable to 455 clinical risk factors for ischaemic stroke. *Nat Commun* **10**, 1–10 (2019).
- Thomas, E. A. *et al.* Polygenic Risk, Midlife Life's Simple 7, and Lifetime Risk of
 Stroke. *J Am Heart Assoc* 11, (2022).
- 458 16. Hachiya, T. *et al.* Genetic Predisposition to Ischemic Stroke: A Polygenic Risk Score.
 459 *Stroke* 48, 253–258 (2017).
- 46017.Hachiya, T. et al. Genome-wide polygenic score and the risk of ischemic stroke in a461prospective cohort: The Hisayama study. Stroke 759–765 (2020)

462		doi:10.1161/STROKEAHA.119.027520.
463	18.	Mishra, A. et al. Stroke genetics informs drug discovery and risk prediction across
464		ancestries. Nature (2022) doi:10.1038/s41586-022-05165-3.
465	19.	Howe, L. J. et al. Polygenic risk scores for coronary artery disease and subsequent
466		event risk amongst established cases. Hum Mol Genet 29, 1388–1395 (2020).
467	20.	Dahabreh, I. J. & Kent, D. M. Index Event Bias as an Explanation for the Paradoxes
468		of Recurrence Risk Research. https://iamanetwork.com/.
469	21	Ni G et al A Comparison of Ten Polygenic Score Methods for Psychiatric Disorders
470	211	Applied Across Multiple Cohorts <i>Biol Psychiatry</i> 90 611–620 (2021)
471	22	Hahn G <i>et al.</i> A Smoothed Version of the Lassosum Penalty for Fitting Integrated
472	22.	Risk Models Using Summary Statistics or Individual-Level Data Genes (Rasel) 13
473		(2022)
474	23	Osterman M D Kinzy T G & Bailey I N C Polygenic Risk Scores Curr Protoc
475 175	23.	1 (2021)
475	24	7 has 7 Song I Wang T & Lu O Polygenic risk scores: affect estimation and
470	24.	Σ and Σ , solid, Σ , wang, Γ & Σu , Q . Polygenic Tisk scores. effect estimation and model entimization <i>Quantitative Biology</i> 0 (2021)
477	25	Mo V & Thou V Constin prediction of complex traits with polyconic scores: a
470	23.	Ma, I. & Zhou, A. Genetic prediction of complex trans with polygenic scores. a
4/9	20	Statistical review. Trends in Genetics 57, 993–1011 (2021).
480	26.	Pain, O. <i>et al.</i> Evaluation of polygenic prediction methodology within a reference-
481	27	standardized framework. PLos Genet 17, $1-22$ (2021).
482	27.	Zhang, Q., Prive, F., Vilnjalmsson, B. & Speed, D. Improved genetic prediction of
483		complex traits from individual-level data or summary statistics. <i>Nat Commun</i> 12, 1–9
484	•	(2021).
485	28.	Yang, S. & Zhou, X. PGS-server: accuracy, robustness and transferability of polygenic
486	•	score methods for biobank scale studies. <i>Brief Bioinform</i> 23, 1–19 (2022).
487	29.	Wang, Y., Tsuo, K., Kanai, M., Neale, B. M. & Martin, A. R. Challenges and
488		opportunities for developing more generalizable polygenic risk scores. 293–320
489		(2022).
490	30.	Kulm, S., Marderstein, A., Mezey, J. & Elemento, O. A systematic framework for
491		assessing the clinical impact of polygenic risk scores. medRxiv preprint doi:
492		https://doi.org/10.1101/2020.04.06.20055574 (2021)
493		doi:10.1101/2020.04.06.20055574.
494	31.	Nagai, A. et al. Overview of the BioBank Japan Project: Study design and profile. J
495		<i>Epidemiol</i> 27 , S2–S8 (2017).
496	32.	Hirata, M. et al. Cross-sectional analysis of BioBank Japan clinical data: A large
497		cohort of 200,000 patients with 47 common diseases. <i>J Epidemiol</i> 27, S9–S21 (2017).
498	33.	Hirata, M. et al. Overview of BioBank Japan follow-up data in 32 diseases. J
499		<i>Epidemiol</i> 27 , S22–S28 (2017).
500	34.	Chang, C. C. et al. Second-generation PLINK: Rising to the challenge of larger and
501		richer datasets. Gigascience 4, 1–16 (2015).
502	35.	Purcell, S. et al. PLINK: A tool set for whole-genome association and population-
503		based linkage analyses. Am J Hum Genet 81, 559–575 (2007).
504	36.	Marees, A. T. et al. A tutorial on conducting genome-wide association studies: Quality
505		control and statistical analysis. Int J Methods Psychiatr Res 27, 1–10 (2018).
506	37.	Choi, S. W., Mak, T. S. H. & O'Reilly, P. F. Tutorial: a guide to performing polygenic
507		risk score analyses. <i>Nat Protoc</i> 15 , 2759–2772 (2020).
508	38.	Koyama, S. et al. Population-specific and trans-ancestry genome-wide analyses
509		identify distinct and shared genetic risk loci for coronary artery disease. <i>Nat Genet</i> 52.
510		1169–1177 (2020).
511	39.	Privé, F., Arbel, J. & Vilhiálmsson, B. J. LDpred2: Better, faster, stronger
	- / •	, ,

- 512 *Bioinformatics* **36**, 5424–5431 (2020).
- 40. Privé, F., Arbel, J., Aschard, H. & Vilhjálmsson, B. J. Identifying and correcting for
 misspecificationsin GWAS summary statistics and polygenic scores. *Human Genetics and Genomics Advances* 100136 (2022) doi:10.1016/j.xhgg.2022.100136.
- 516 41. Ge, T., Chen, C. Y., Ni, Y., Feng, Y. C. A. & Smoller, J. W. Polygenic prediction via 517 Bayesian regression and continuous shrinkage priors. *Nat Commun* **10**, 1–10 (2019).
- Kuan, Y. *et al.* Improving polygenic prediction in ancestrally diverse populations. *Nat Genet* (2022) doi:10.1038/s41588-022-01054-7.
- Malik, R. *et al.* Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. *Nat Genet* 50, 524–537 (2018).
- 523 44. Nagelkerke N. J. D. A Note on a General Definition of the Coefficient of
 524 Determination. *Biometrika* 78, 691–692 (1991).
- 45. Wang, Y. *et al.* Global Biobank analyses provide lessons for developing polygenic risk
 scores across diverse cohorts. *Cell Genomics* 3, (2023).
- 46. Hindy, G. *et al.* Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease. *Arterioscler Thromb Vasc Biol* 2738–2746 (2020) doi:10.1161/ATVBAHA.120.314856.
- Mitchell, R. E. *et al.* Strategies to investigate and mitigate collider bias in genetic and
 Mendelian randomisation studies of disease progression. *PLoS Genetics* vol. 19
 Preprint at https://doi.org/10.1371/journal.pgen.1010596 (2023).
- 48. Sep, S. J., Van Kuijk, S. M. & Smits, L. J. Index event bias: Problems with eliminating
 the paradox. *Journal of Stroke and Cerebrovascular Diseases* vol. 23 2464 Preprint at
 https://doi.org/10.1016/j.jstrokecerebrovasdis.2014.06.025 (2014).
- 49. Levine, D. A. *et al.* Smoking and mortality in stroke survivors: Can we eliminate the
 paradox? *Journal of Stroke and Cerebrovascular Diseases* 23, 1282–1290 (2014).
- 538 50. Altman, D. G. & Bland, J. M. Interaction revisited: The difference between two 539 estimates. *BMJ* **326**, 219 (2003).
- 540 51. Ishigaki, K. *et al.* Large-scale genome-wide association study in a Japanese population
 541 identifies novel susceptibility loci across different diseases. *Nat Genet* 52, 669–679
 542 (2020).
- 543 52. Bulik-Sullivan, B. *et al.* LD score regression distinguishes confounding from 544 polygenicity in genome-wide association studies. *Nat Genet* **47**, 291–295 (2015).
- 545 53. Cho, S. M. J. *et al.* Genetic, sociodemographic, lifestyle, and clinical risk factors of
 546 recurrent coronary artery disease events: a population-based cohort study. *Eur Heart J*547 (2023) doi:10.1093/eurheartj/ehad380.
- 54854.Weale, E. M. Quality control for genome-wide association studies. Methods Mol Biol549(2010) doi:10.1007/978-1-60327-367-1_19.
- 550 55. Akiyama, M. *et al.* Characterizing rare and low-frequency height-associated variants 551 in the Japanese population. *Nat Commun* **10**, (2019).
- 552 56. Privé, F., Vilhjálmsson, B. J., Aschard, H. & Blum, M. G. B. Making the Most of
 553 Clumping and Thresholding for Polygenic Scores. *Am J Hum Genet* 105, 1213–1221
 554 (2019).
- 555 57. Chagnon, M., O'Loughlin, J., Engert, J. C., Karp, I. & Sylvestre, M. P. Missing single
 556 nucleotide polymorphisms in Genetic Risk Scores: A simulation study. *PLoS One* 13,
 557 1–14 (2018).
- 58. Goldstein, B. A., Yang, L., Salfati, E. & Assimes, T. L. Contemporary Considerations
 for Constructing a Genetic Risk Score: An Empirical Approach. *Genet Epidemiol* 39, 439–445 (2015).
- 561 59. Wang, Y. et al. Global Biobank analyses provide lessons for developing polygenic risk

562 scores across diverse cohorts. *Cell Genomics* **3**, (2023).

- 563 60. Tadaka, S. *et al.* jMorp updates in 2020: Large enhancement of multi-omics data
 564 resources on the general Japanese population. *Nucleic Acids Res* 49, D536–D544
 565 (2021).
- 61. Restuadi, R. *et al.* Polygenic risk score analysis for amyotrophic lateral sclerosis
 leveraging cognitive performance, educational attainment and schizophrenia. *European Journal of Human Genetics* (2021) doi:10.1038/s41431-021-00885-y.
- 569 62. Turley, P. *et al.* Multi-trait analysis of genome-wide association summary statistics
 570 using MTAG. *Nat Genet* 50, 229–237 (2018).
- 571 63. Maier, R. M. *et al.* Improving genetic prediction by leveraging genetic correlations
 572 among human diseases and traits. *Nat Commun* 9, 1–17 (2018).
- 573 64. Ho, W. K. *et al.* European polygenic risk score for prediction of breast cancer shows
 574 similar performance in Asian women. *Nat Commun* 11, 1–11 (2020).
- 575 65. Amariuta, T. *et al.* Improving the trans-ancestry portability of polygenic risk scores by
 576 prioritizing variants in predicted cell-type-specific regulatory elements. *Nat Genet* 52,
 577 1346–1354 (2020).
- 578

580 Tables

581

582 Table 1. Characteristic of the testing sample (BBJ2)

583

	Any-AIS versus AIS-free controls			Recurrent AIS versus non-recurrent AIS				
	N sample (%, SD)	OR	95% CI	p- value	N sample (%, SD)	OR	95% CI	p- value
Total participants	41,929 (100%)	-	-	-	1,327 (100%)	-	-	-
AIS / AIS recurrent	1,470 (3.5%)	-	-	-	174 (13.1%)	-	-	-
Age (SD)*	70.0 (SD=12.6)	1.18	[1.06– 1.31]	0.002	64.1 (SD=11.5)	0.83	[0.59– 1.16]	0.256
Female sex	19,407 (46.3%)	0.48	[0.43– 0.54]	< 0.001	383 (28.9%)	0.63	[0.42– 0.93]	0.019
Hypertensio n	17,710 (42.2%)	2.27	[2.04– 2.53]	< 0.001	838 (63.1%)	0.92	[0.66– 1.3]	0.673
Hyperlipide mia	11,604 (27.7%)	2.17	[1.95– 2.41]	< 0.001	603 (45.4%)	0.92	[0.66– 1.29]	0.625
Diabetes	3,622 (8.6%)	1.16	[0.97– 1.39]	0.089	125 (9.4%)	0.97	[0.52– 1.7]	1.000
Smoking ^{**}	21,570 (51.9%)	1.43	[1.28– 1.59]	< 0.001	795 (60.5%)	1.28	[0.90– 1.82]	0.179
Vascular disease	3,136 (7.5%)	1.31	[1.08– 1.56]	0.005	122 (9.2%)	1.08	[0.59– 1.87]	0.778
Heart failure	1,329 (3.2%)	1.27	[0.95– 1.66]	0.095	48 (3.6%)	1.79	[0.78– 3.75]	0.124
Atrial fibrillation	1,004 (2.4%)	2.22	[1.71– 2.84]	<0.001	65 (4.9%)	1.07	[0.46– 2.23]	0.850

All risk factor characteristics were derived from history and not at the time of registration.
Odds ratio (OR), 95% CI (95% confidence intervals, and p-values were calculated using
logistic regression for onset and AIS recurrence (unadjusted for other factors). *Age at AIS

588	case-control was that at recruitment, while age at recurrent AIS case-control was that at first
589	incidence. The numbers indicate the median threshold age. ** The total number of missing
590	values of smoking was 389 for all case-control and 12 for recurrent AIS case-control
591	samples. Abbreviations: BBJ2, BioBank 2 nd cohort; AIS, all ischemic stroke; SD = standard
592	deviation

Table 2. Polygenic risk score performance at validation

Method	Best parameters	Mean number of variants	Best mean incremental Nagelkerke R ²	Standard deviation	95% confidence interval
P+T	Clumping R ² =0.95, Clumping kb=526, Imputation R ² =0.8, p-value threshold=1	3,144,737	0.0038	0.0012	0.0030– 0.0046
LDpred2	ρ value=0.0056, heritability value x 1.0, no_sparse	898,456	0.00443	0.0013	0.0035– 0.0054
Lassosum2	S=0.9, lambda=0.00388	282,520	0.0039	0.0013	0.0030– 0.0048
PRS-CS	Phi=1.00E-04	985,439	0.00441	0.0012	0.0036– 0.0053
PRS-CSx	Phi=1.00E-05	1,016,745	0.0037	0.0008	0.0031– 0.0042

598 Table 3. Polygenic risk score performance at testing

599

PRS Method	Association tests	OR per SD [95% CI]	p-value	Incre- mental AUC	Incremental Nagelkerke R ²
MateCDC	AIS	1.21[1.15–1.27]	2.89E-12	0.0087	0.0044
MetaGKS	Recurrence	1.18[1.00–1.39]	0.044	0.0123	0.0057
MEGASTROKE	AIS	1.11[1.06–1.17]	4.23E-05	0.0033	0.0015
27 SNVs	Recurrence	1.07[0.91–1.25]	0.41	0.0032	0.0009
GIGASTROKE	AIS	1.08[1.03–1.14]	2.96E-03	0.0022	0.0008
84 SNVs	Recurrence	1.17[1.00–1.38]	0.054	0.0125	0.0052
GIGASTROKE	AIS	1.26[1.20–1.33]	1.24E-17	0.0130	0.0066
iPGS	Recurrence	1.08[0.91–1.27]	0.37	0.0044	0.0011

600

Polygenic risk score performance was evaluated using an independent testing set for AIS and recurrent AIS. We showed two main association tests; AIS (any-AIS cases vs. AIS-free controls) and AIS recurrence (recurrent AIS vs. non-recurrent AIS). Incremental AUC and R^2 are the differences in the values when fitting with/without PRS, along with age, sex, the first 10 PCs, and seven risk factors. Abbreviations: AIS, all ischemic strokes; OR, odds ratio; AUC, area under the curve; PC, principal components; PRS, polygenic risk score; SD = standard deviation

609 Figure Legends

610 Figure 1. Workflow



611

612 MEGASTROKE AIS summary statistics of European (EUR) studies were only used for 613 PRS-CSx. 1000 Genomes Project super population samples (EAS or EUR) were used for the 614 LD reference panel. Abbreviations: GWAS = genome-wide association study, PRS = 615 polygenic risk score, P+T = pruning and thresholding, OR = odds ratio, AIS = all ischemic 616 stroke, ToMMo = Tohoku Medical Megabank; LD, linkage disequilibrium.

We used a logistic regression model to assess the association of the PRS using the two casecontrol settings for AIS (A: any-AIS vs. AIS-free controls) and AIS recurrence (B: recurrent AIS vs. non-recurrent AIS). We also applied two other combinations of case-controls (C: recurrent versus AIS-free controls and D: non-recurrent versus AIS-free controls).

622 Figure 2. Odds ratio of metaGRS tertiles with/without a history of hypertension



625 Association of AIS recurrence and meta-GRS tertiles with or without a history of 626 hypertension (HT) in the testing sample, with reference to the low metaGRS tertiles.

634	
635	SUPPLEMENTARY MATERIALS
636	
637	
638	Recurrent stroke prediction by applying a stroke polygenic risk score
639	in the Japanese population
640	
641	
642	

643 Supplementary Methods

644

645 Samples

646 BioBank Japan (BBJ) collected DNA, serum, and medical records (clinical information) with

647 consent from patients. The BBJ 1st cohort (BBJ1) dataset contained all ischemic stroke (AIS,

648 n=17,621) cases, including large artery stroke (LAS, n=981), small vessel stroke (SVS,

649 n=3,108), and cardioembolic stroke (CES, n=608) cases. The patients without AIS were 650 included as controls (n=162,317).

Testing involved the use of data from part of the BBJ 2nd cohort (BBJ2) dataset, which 651 contains information about AIS cases (n=1,470), including LAS (n=268), SVS (n=508), CES 652 (n=122), and transient ischemic attack (TIA, n=105). All patients without AIS were included 653 654 as controls (n=40,459). Among these cases, recurrent ischemic stroke (n=187) was used as a case of recurrent AIS, which included LAS (n=40), SVS (n=57), CES (n=11), and transient 655 656 ischemic attack (TIA, n=20). Samples with information on the first onset date and follow-up 657 of under 30 days were excluded; AIS cases with recurrence (n=174) were set as the case group, and AIS cases without recurrence (n=1,153) remained in the control group in the 658 659 testing sample.

660

661 Quality control and imputation process of BBJ1 data

We removed variants with call rates <0.99, samples with call rates <0.98, non-East Asian samples, and sex-discordant samples. We used 939 samples whose genotypes were analyzed using whole-genome sequencing (WGS); we added an additional quality control based on the concordance rate between the genotyping array and WGS. We excluded variants with concordance rates <99.5% or non-reference discordance rates \geq 0.5% and Hardy-Weinberg equilibrium (HWE) (p<1e-6). The 10 principal components (PCs) were calculated by applying additional quality control (QC) to the BBJ1 genotyped data. We removed samples from close relatives (King's cutoff >0.0884), and 24 long LD regions,⁵⁴ including the MHC region (chr6, position 25,000,000-35,000,000), and MAF<0.01. We pruned (PLINK2 parameters: --indep-pairwise 200 50 0.20) and finally used 92,231–92,303 variants to conduct projection and calculate the first 10 PCs depending on a 10-fold sample set of the 90% BBJ1 dataset.

Subsequently, the datasets were phased (Eagle v2.4.1) and imputed (Minimac4 v1.0.2) using the developed panel.⁵⁵ We further conducted quality control to remove variants with minor allele counts <10, close relatives (King cutoff >0.0884), and imputation r-square <0.8.

677

678 Quality control and imputation process for BBJ2 data

We removed samples with no age/sex information, sex discrepancy, call rates <0.98, heterozygosity rates with SD >4 or <- 4, from duplicate or twins (pi-hat >= 0.75), and from non-East Asian subjects. We then removed variants with a call rate <0.99, duplicate SNPs, heterozygous count <5, HWE (p<1e-6), and allele frequency discrepancies (gap from 1000 genomes EAS >0.16). A total of 41,929 samples and 525,239 variants were analyzed.

We applied additional quality control to the BBJ2 genotyped data to calculate the 10 PCs. We removed variants in 24 long LD regions,⁵⁴ pruned them (PLINK2 parameters: --indeppairwise 200 50 0.05), extracted close relatives (King cut-off >0.0884), and used 69,068 variants to calculate the first 10 PCs.

688 We removed variants of the imputation r-squared <0.3 after phasing (Eagle v2.4.1) and

689 imputing (Minimac4 v1.0.2) the developed panel.⁵⁵ We used a lower r-square threshold for
690 BBJ2 to reduce the number of variants unmatched with BBJ1.

691

692 **Polygenic risk score parameters at the derivation**

693 Pruning and threshold used a total of 1,224 parameter combinations of three stricter imputation r-squared score thresholds {0.8, 0.9, and 0.95}, four base sizes of the clumping 694 695 696 0.8, and 0.95}, and 17 p-value threshold {1e-8, 3e-8, 1e-7, 3e-7, 1e-6, 3e-6, 1e-5, 3e-5, 1e-4, 3e-4, 1e-3, 3e-3, 0.01, 0.03, 0.1, 0.3, and 1}. We used clumping windows and divided the 697 base size by the squared correlation of clumping.^{56–59} The following default parameters were 698 used for LDpred2: three heritability $\{0.7, 1, \text{ and } 1.4\} \times h^2_{LDSC}$, where h^2_{LDSC} is the heritability 699 estimate from the constrained LD score regression, ⁵² 21 ρ estimates {equally spaced on a log 700 701 scale between 1e-5 and 1}, and sparse or not. The following default parameters were used for 702 Lassosum2: 10 values of s {0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, and 1.0} and 20 values of λ {equally spaced on a log scale between 0.1 and 0.001}. Regarding PRS-CS and PRS-CSx, 703 704 we used slightly more extended parameters: phi {1e-7, 1e-6, 1e-5, 1e-4, 1e-3, 0.01, 0.1, 1, 705 and auto}, than the default parameters {1e-4, 1e-3, 0.01, 0.1, 1, and auto}, because the 706 optimized parameter in the initial trials using our dataset was the smallest (phi=1e-4) in the default range. Other parameters were set to default values (a=1, b=0.5).^{41,42} 707

708

709 Linkage disequilibrium (LD) reference

We used the EAS superpopulation of the 1000 Genomes panel (n=504) as a LD reference for P+T clumping. For Ldpred2, Lassosum2, PRS-CS, and PRS-CSx models, we restricted our use of external LD reference panels to the HapMap 3 variants, which were also constructed from 1000 Genomes EAS. HapMap 3 variant restriction resulted in 898,456, 898,456, 985,440, and 1,076,835 variants of Ldpred2, Lassosum2, PRS-CS, and PRS-CSx, respectively. To use PRS-CSx for the EUR, we used the EUR superpopulation of the 1000 Genomes panel and its HapMap3 variants (1,016,745 variants).

718 Genome wide association study summary statistics for metaGRS construction

MetaGRS was developed following a previous study¹⁴ and included nine binary and eight 719 quantitative traits. The nine binary traits were SVS, LAS, CES, myocardial infarction (MI), 720 721 stable angina pectoris (SAP), unstable angina pectoris (AP), atrial fibrillation (AF), diabetes (DM), and ever smoking (SM) from the BBJ1 dataset. Subsequently, we conducted GWAS. 722 The number of cases and controls is listed in Table S15. Summary statistics were obtained 723 724 from the jMorp website (https://jmorp.megabank.tohoku.ac.jp) and were used for eight quantitative traits-body mass index (BMI), height (HE), systolic blood pressure (SBP), 725 726 diastolic blood pressure (DBP), total cholesterol (TC), triglyceride (TG), high-density 727 lipoprotein (HDL), and low-density lipoprotein (LDL) from the Tohoku Medical Megabank Project (ToMMo; 22,033 to 47,056 samples).⁶⁰ 728

729

730 **Polygenic risk score calculation from other milestone studies**

We obtained effect weights from the PGS catalog (PGS000665 and PGS002725 of https://www.pgscatalog.org_for PRS₃₂ and iPGS_{EAS}, respectively) and for PRS₈₉ from the supplementary tables.¹⁸ We used variants that matched with the BBJ2 dataset (imputation rsquared > 0.3). The unmatched variants in PRS₃₂ and PRS₈₉ included proxy variants that showed the highest r-squared values with the index variants only from an r-squared value greater than 0.3. The r-squared values were calculated using the plink --r2 command³⁵ with the 1000 Genome EAS as a reference.

739 Supplementary Notes

740

741 Characteristics of the PRS methods during validation

742 The following characteristics of each method were observed while testing several parameters: the best mean incremental R^2 of 0.0038 was observed for the P + T method when 743 we liberalized the p-value threshold to 1 and clumped $r^2 > 0.8$, whereas it was below 0.001 744 when we used a low p-value threshold ($<10^{-8}$, Table S5). For LDpred2, ρ values higher than 745 0.001 showed good performance (mean incremental R² was 0.0038 for ρ values >=0.001 746 747 compared to 0.0016 for ρ values <0.001), while heritability estimates and sparse parameters made less difference (Table S6). For Lassosum2, the closer the value of parameter "s" is to 1, 748 the higher the prediction accuracy, but it wasn't the case at exactly 1. Larger lambda 749 parameters correlate with greater accuracy (mean incremental R² was between 0.0025 to 750 0.0039). However, the accuracy sharply decreases (mean incremental $R^2 < 0.001$) if the value 751 752 is too small (<0.01). The prediction performance was maximized when the parameters were 753 s=0.9 and lambda=0.0038 (Table S7). High and low phi values resulted in low performance for PRS-CS (mean incremental R² was 0.0041 for phi=10⁻³, 10⁻⁴, and 10⁻⁵ compared to 754 755 0.0029 for other phi parameters; Table S8). Meanwhile, PRS-CSx was relatively consistent regardless of the phi values (mean incremental R^2 was 0.0032 for phi=10⁻³, 10⁻⁴, and 10⁻⁵ 756 compared to 0.0028 for other phi parameters; Table S9). 757

The performance of the PRS-CS ($R^2=0.00441$) was comparable to that of LDpred2 ($R^2=0.00443$) in the validation analysis. Low validation predictability (incremental $R^2 < 0.001$) was observed when we restricted the p-value threshold in the P+T method to genomewide significance ($p < 5 \times 10^{-8}$). PRS-CSx improves cross-population polygenic prediction by integrating GWAS summary statistics from other populations;^{61–65} however, we could not reproduce this result in our current study using PRS-CSx. Our results demonstrate the

- 764 importance of using Bayesian methods of high-dimensional techniques in variable selection
- and shrinkage estimation considering LD (such as LDpred2 and PRS-CS) to predict AIS and
- recurrent AIS.

767

769 Supplementary Figures

770

771 Figure S1. Genome-wide association study (GWAS) in derivation samples

We conducted stroke GWAS using 90% of BBJ 1st cohort data as the derivation sample, using Firth logistic <u>ب</u> each 10-fold cross-validation identification. a. Quantile-Quantile plot, Manhattan plot, and c. genome-wide significant ($p \le 5e-8$) loci of each fold. Abbreviations: Chr = chromosome. regression and PLINK (v.2.0) for



773



774

775

776 Figure S2. Elastic net weight

777 The mean weight of 10-fold elastic net regression as determined by "glmnet" in the 778 validation sample. The X-axis shows the AS and the 17 binary and quantitative traits. Error 779 bars represent standard deviations.

Abbreviations: AIS, all ischemic stroke; SVS, small vessel stroke; LAS, large artery stroke;
CES, cardioembolic stroke; MI, myocardial infarction; SAP, stable angina pectoris; UAP,
unstable angina pectoris; AF, atrial fibrillation; DM, diabetes; SM, smoking; BMI, body mass
index; HE, height; SBP, systolic blood pressure; DBP, diastolic blood pressure; TC, total
cholesterol; TG, triglyceride; HCL, high-density lipoprotein; LDL, low-density lipoprotein;
SD, standard deviation.

786



788

789

790 Figure S3. Odds ratio per SD to predict AIS and AIS recurrence

Odds ratio per standard deviation by metaGRS and three publicly available PRS in the independent test set of AIS (case=1, 470, control=40,459) and AIS recurrence case-control set (case=174, control=1,153). Age, sex, the first 10 PCs, and seven risk factors were adjusted. Error bars represent 95% confidence intervals. The dotted line represents the point at which the ORs per SD of AIS and AIS recurrence were equal. Abbreviations: OR, odds ratio; AIS, all ischemic stroke; PRS, polygenic risk score; PC, principal component; SD, standard deviation.







801 Figure S4. Association between seven comorbidities and AIS/AIS recurrence

The Y-axis shows the odds ratio per standard deviation (SD) and 95% confidence interval (CI) of the seven risk factors (six clinical comorbidities and smoking) in the BBJ 2nd cohort. In our dataset, we used HT defined as SBP>140 mmHg, DBP>90 mmHg, or hypertension history, DM inclusive of type 1 diabetes and other diabetes, SM as a current smoker at the time of registration, VD representing myocardial infarction, arteriosclerosis obliterans, stable angina pectoris, unstable angina pectoris, and AF inclusive of atrial flutter. We used the status at the time of registration and history of these comorbidities.

809 Abbreviations: HT, hypertension; HL, hyperlipidemia; DM, diabetes; SM, smoking; VD,

810 vascular disease; HF, congestive heart failure; AF, atrial fibrillation.



812



814 Figure S5. Association between metaGRS and AIS recurrence in patients with or
815 without IPW adjustment

The y-axis shows the odds ratio per SD and the 95% confidence interval for predicting recurrent AIS. Model 1: age and sex; model 2: age, sex, and seven risk factors; model 3: age, sex, the first 10 principal components (PCs), and seven risk factors. The color represents whether the inverse probability weight (IPW) is adjusted. We applied logistic regression using variables as covariates when the IPW was not adjusted. We replaced 14 missing data on the smoking status to mean values.

823 Supplementary Tables

824 In separate spreadsheets S1-15

825

826

828 **Consortium authors**

829

830 BioBank Japan

- Koichi Matsuda^{1,2}, Yuji Yamanashi³, Yoichi Furukawa⁴, Takayuki Morisaki⁵, Yoshinori
 Murakami⁶, Yoichiro Kamatani^{2,7}, Kaori Muto⁸, Akiko Nagai⁸, Wataru Obara⁹, Ken Yamaji¹⁰,
 Kazuhisa Takahashi¹¹, Satoshi Asai^{12,13}, Yasuo Takahashi¹³, Takao Suzuki¹⁴, Nobuaki
 Sinozaki¹⁴, Hiroki Yamaguchi¹⁵, Shiro Minami¹⁶, Shigeo Murayama¹⁷, Kozo Yoshimori¹⁸,
 Satoshi Nagayama¹⁹, Daisuke Obata²⁰, Masahiko Higashiyama²¹, Akihide Masumoto²²,
- 836 Yukihiro Koretsune²³

- ¹Laboratory of Genome Technology, Human Genome Center, Institute of Medical Science,
 The University of Tokyo, Tokyo, Japan.
- ²Laboratory of Clinical Genome Sequencing, Graduate School of Frontier Sciences, The
 University of Tokyo, Tokyo, Japan.
- ³Division of Genetics, The Institute of Medical Science, The University of Tokyo, Tokyo,
 Japan.
- ⁴Division of Clinical Genome Research, Institute of Medical Science, The University of
 Tokyo, Tokyo, Japan.
- ⁵Division of Molecular Pathology IMSUT Hospital, Department of Internal Medicine Project
- 847 Division of Genomic Medicine and Disease Prevention The Institute of Medical Science The
- 848 University of Tokyo, Tokyo, Japan.
- ⁶Department of Cancer Biology, Institute of Medical Science, The University of Tokyo,
 Tokyo, Japan.
- ⁷Laboratory of Complex Trait Genomics, Graduate School of Frontier Sciences, The
- 852 University of Tokyo, Tokyo, Japan.

- ⁸Department of Public Policy, Institute of Medical Science, The University of Tokyo, Tokyo,
- 854 Japan.
- ⁹Department of Urology, Iwate Medical University, Iwate, Japan.
- ¹⁰Department of Internal Medicine and Rheumatology, Juntendo University Graduate School
- 857 of Medicine, Tokyo, Japan.
- 858 ¹¹Department of Respiratory Medicine, Juntendo University Graduate School of Medicine,
- 859 Tokyo, Japan.
- 860 ¹²Division of Pharmacology, Department of Biomedical Science, Nihon University School of
- 861 Medicine, Tokyo, Japan.
- 862 ¹³Division of Genomic Epidemiology and Clinical Trials, Clinical Trials Research Center,
- 863 Nihon University. School of Medicine, Tokyo, Japan.
- 864 ¹⁴Tokushukai Group, Tokyo, Japan.
- 865 ¹⁵Hiroki Yamaguchi. Department of Hematology, Nippon Medical School, Tokyo, Japan.
- 866 ¹⁶Department of Bioregulation, Nippon Medical School, Kawasaki, Japan.
- ¹⁷Shigeo Murayama. Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology,
 Tokyo, Japan.
- 869 ¹⁸Fukujuji Hospital, Japan Anti-Tuberculosis Association, Tokyo, Japan.
- ¹⁹The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo,
 Japan.
- ²⁰Center for Clinical Research and Advanced Medicine, Shiga University of Medical
 Science, Shiga, Japan.
- 874 ²¹Masahiko Higashiyama. Department of General Thoracic Surgery, Osaka International
- 875 Cancer Institute, Osaka, Japan.
- 876 ²²Iizuka Hospital, Fukuoka, Japan.
- 877 ²³National Hospital Organization Osaka National Hospital, Osaka, Japan.

880881 MEGASTROKE CONSORTIUM

Rainer Malik¹, Ganesh Chauhan², Matthew Traylor³, Muralidharan Sargurupremraj^{4,5}, Yukinori Okada^{6,7,8}, Aniket Mishra^{4,5}, Loes Rutten-Jacobs³, Anne-Katrin Giese⁹, Sander W van der Laan¹⁰, Solveig Gretarsdottir¹¹, Christopher D Anderson^{12,13,14}, Michael Chong¹⁵, Hieab HH Adams^{16,17}, Tetsuro Ago¹⁸, Peter Almgren¹⁹, Philippe Amouyel^{20,21}, Hakan Ay^{13,22}, Traci M Bartz²³, Oscar R Benavente²⁴, Steve Bevan²⁵, Giorgio B Boncoraglio²⁶, Robert D Brown, Jr.²⁷, Adam S Butterworth^{28,29}, Caty Carrera^{30,31}, Cara L Carty^{32,33}, Daniel I Chasman^{34,35}, Wei-Min Chen³⁶, John W Cole³⁷, Adolfo Correa³⁸, Ioana Cotlarciuc³⁹, Carlos Cruchaga^{40,41}, John Danesh^{28,42,43,44}, Paul IW de Bakker^{45,46}, Anita L DeStefano^{47,48}, Marcel den Hoed⁴⁹, Qing Duan⁵⁰, Stefan T Engelter^{51,52}, Guido J Falcone^{53,54}, Rebecca F Gottesman⁵⁵, Raji P Grewal⁵⁶, Vilmundur Gudnason^{57,58}, Stefan Gustafsson⁵⁹, Jeffrey Haessler⁶⁰, Tamara B Harris⁶¹, Ahamad Hassan⁶², Aki S Havulinna^{63,64}, Susan R Heckbert⁶⁵, Elizabeth G Holliday^{66,67}, George Howard⁶⁸, Fang-Chi Hsu⁶⁹, Hyacinth I Hyacinth⁷⁰, M Arfan Ikram¹⁶, Erik Ingelsson^{71,72}, Marguerite R Irvin⁷³, Xueqiu Jian⁷⁴, Jordi Jiménez-Conde⁷⁵, Julie A Ingelsson^{71,72}, Marguerite R Irvin⁷³, Xueqiu Jian⁷⁴, Jordi Jiménez-Conde⁷⁵, Julie A Johnson^{76,77}, J Wouter Jukema⁷⁸, Masahiro Kanai^{6,7,79}, Keith L Keene^{80,81}, Brett M Kissela⁸², Dawn O Kleindorfer⁸², Charles Kooperberg⁶⁰, Michiaki Kubo⁸³, Leslie A Lange⁸⁴, Carl D Langefeld⁸⁵, Claudia Langenberg⁸⁶, Lenore J Launer⁸⁷, Jin-Moo Lee⁸⁸, Robin Lemmens^{89,90}, Didier Leys⁹¹, Cathryn M Lewis^{92,93}, Wei-Yu Lin^{28,94}, Arne G Lindgren^{95,96}, Erik Lorentzen⁹⁷, Patrik K Magnusson⁹⁸, Jane Maguire⁹⁹, Ani Manichaikul³⁶, Patrick F McArdle¹⁰⁰, James F Meschia¹⁰¹, Braxton D Mitchell^{100,102}, Thomas H Mosley^{103,104}, Michael A Nalls^{105,106}, Toshiharu Ninomiya¹⁰⁷, Martin J O'Donnell^{15,108}, Bruce M Psaty^{109,110,111,112}, Sara L Pulit^{45,113}, Kristiina Rannikmäe^{114,115}, Alexander P Reiner^{65,116}, Kathryn M Rexrode¹¹⁷, Kenneth Rice¹¹⁸, Stephen S Rich³⁶, Paul M Ridker^{34,35}, Natalia S Rost^{9,13}, Peter M Rothwell¹¹⁹, Jerome I Rotter^{120,121}, Tatjana Rundek¹²², Ralph L Sacco¹²², Saori Sakaue^{7,123}, Michele M Sale¹²⁴, Veikko Salomaa⁶³, Bishwa R Sapkota¹²⁵, Reinhold Schmidt¹²⁶, Carsten O Schmidt¹²⁷, Ulf Schminke¹²⁸, Pankaj Sharma³⁹, Agnieszka Slowik¹²⁹, Cathie LM Sudlow^{114,115}, Christian Tanislav¹³⁰, Turgut Tatlisumak^{131,132}, Slowik¹²⁹, Cathie LM Sudlow^{114,115}, Christian Tanislav¹³⁰, Turgut Tatlisumak^{131,132}, Kent D Taylor^{120,121}, Vincent NS Thijs^{133,134}, Gudmar Thorleifsson¹¹, Unnur Kent D Taylor^{120,121}, Vincent NS Thijs^{133,134}, Gudmar Thorleifsson¹¹, Unnur Thorsteinsdottir¹¹, Steffen Tiedt¹, Stella Trompet¹³⁵, Christophe Tzourio^{5,136,137}, Cornelia M van Duijn^{138,139}, Matthew Walters¹⁴⁰, Nicholas J Wareham⁸⁶, Sylvia Wassertheil-Smoller¹⁴¹, James G Wilson¹⁴², Kerri L Wiggins¹⁰⁹, Qiong Yang⁴⁷, Salim Yusuf¹⁵, Najaf Amin¹⁶, Hugo S Aparicio^{48,185}, Donna K Arnett¹⁸⁶, John Attia¹⁸⁷, Alexa S Beiser^{47,48}, Claudine Berr¹⁸⁸, Julie E Buring^{34,35}, Mariana Bustamante¹⁸⁹, Valeria Caso¹⁹⁰, Yu-Ching Cheng¹⁹¹, Seung Hoan Choi^{48,192}, Ayesha Chowhan^{48,185}, Natalia Cullell³¹, Jean-François Dartigues^{193,194}, Hossein Delavaran^{95,96}, Pilar Delgado¹⁹⁵, Marcus Dörr^{196,197}, Gunnar Engström¹⁹, Ian Ford¹⁹⁸, Wander S Gurpreet¹⁹⁹, Anders Hamsten^{200,201}, Laura Heitsch²⁰², Atsushi Hozawa²⁰³, Laura Ibanez²⁰⁴, Andreea Ilinca^{95,96}, Martin Ingelsson²⁰⁵, Motoki Iwasaki²⁰⁶, Rebecca D Jackson²⁰⁷, Katarina Jood²⁰⁸, Pekka Jousilahti⁶³, Sara Kaffashian^{4,5}, Lalit Kalra²⁰⁹, Masahiro Kamouchi²¹⁰, Takanari Kitazono²¹¹, Olafur Kjartansson²¹², Manja Kloss²¹³, Peter J Koudstaal²¹⁴, Jerzy Krupinski²¹⁵, Daniel L Labovitz²¹⁶, Cathy C Laurie¹¹⁸, Christopher R Levi²¹⁷, Linxin Li²¹⁸, Lars Lind²¹⁹,

Cecilia M Lindgren^{220,221}, Vasileios Lioutas^{48,222}, Yong Mei Liu²²³, Oscar L 927 Leonia William Makoto²²⁵, Nicolas Martinez-Majander¹⁷², Koichi Matsuda²²⁵, Naoko Minegishi²⁰³, Joan Montaner²²⁶, Andrew P Morris^{227,228}, Elena Muiño³¹, Martina Müller-Nurasyid^{229,230,231}, Bo Norrving^{95,96}, Soichi Ogishima²⁰³, Eugenio A Parati²³², Leema Reddy Peddareddygari⁵⁶, Nancy L Pedersen^{98,233}, Joanna Pera¹²⁹, Markus Perola^{63,234}, Alessandro Pezzini²³⁵, Silvana Pileggi²³⁶, Raquel Rabionet²³⁷, Iolanda Riba-Llena³⁰, Marta Ribasés²³⁸, Jose R Romero^{48,185}, Jaume Roquer^{239,240}, Anthony G Rudd^{241,242}, Antti-Pekka Sarin^{243,244}, Ralhan Sarju¹⁹⁹, Chloe Sarnowski^{47,48}, Makoto Sasaki²⁴⁵, Claudia L Satizabal^{48,185}, Mamoru Satoh²⁴⁵, Naveed Sattar²⁴⁶, Norie Sawada²⁰⁶, Gerli Sibolt¹⁷², Ásgeir Sigurdsson²⁴⁷, Albert Smith²⁴⁸, Kenji Sobue²⁴⁵, Carolina Soriano-Tárraga²⁴⁰, Tara Stanne²⁴⁹, O Colin Stine²⁵⁰, David J Stott²⁵¹, Konstantin Strauch^{229,252}, Takako Takai²⁰³, Hideo Tanaka^{253,254}, Kozo Tanno²⁴⁵, Alexander Teumer²⁵⁵, Liisa Tomppo¹⁷², Nuria P Torres-Aguila³¹, Emmanuel Touze^{256,257}, Shoichiro Tsugane²⁰⁶, Andre G Uitterlinden²⁵⁸, Einar M Valdimarsson²⁵⁹, Sven J van der Lee¹⁶, Henry Völzke²⁵⁵, Kenji Wakai²⁵³, David Weir²⁶⁰, Stephen R Williams²⁶¹, Charles DA Wolfe^{241,242}, Quenna Wong¹¹⁸, Huichun Xu¹⁹¹, Taiki Yamaji²⁰⁶, Dharambir K Sanghera^{125,169,170}, Olle Melander¹⁹, Christina Jern¹⁷¹, Daniel Strbian^{172,173}, Israel Fernandez-Cadenas^{31,30}, W T Longstreth, Jr^{65,174}, Arndt Rolfs¹⁷⁵, Jun Hata¹⁰⁷, Daniel Woo⁸², Jonathan Rosand^{12,13,14}, Guillaume Pare¹⁵, Jemma C Hopewell¹⁷⁶, Danish Saleheen¹⁷⁷, Kari Stefansson^{11,178}, Bradford B Worrall¹⁷⁹, Steven J Kittner³⁷, Lopez²²⁴, Hirata Makoto²²⁵, Nicolas Martinez-Majander¹⁷², Koichi Matsuda²²⁵ 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 Saleheen¹⁷⁷, Kari Stefansson^{11,178}, Bradford B Worrall¹⁷⁹, Steven J Kittner³⁷, 947 Sudha Seshadri^{48,180}, Myriam Fornage^{74,181}, Hugh S Markus³, Joanna MM 948 Howson²⁸, Yoichiro Kamatani^{6,182}, Stephanie Debette^{4,5}, Martin Dichgans^{1,183,184} 949 950 951 ¹Institute for Stroke and Dementia Research (ISD), University Hospital, LMU 952 Munich, Munich, Germany ²Centre for Brain Research, Indian Institute of Science, Bangalore, India 953 ³Stroke Research Group, Division of Clinical Neurosciences, University of 954 955 Cambridge, UK ⁴INSERM U1219 Bordeaux Population Health Research Center, Bordeaux, France 956 957 ⁵University of Bordeaux, Bordeaux, France ⁶Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical 958 Sciences, Yokohama, Japan 959 ⁷Department of Statistical Genetics, Osaka University Graduate School of 960 Medicine, Osaka, Japan 961 ⁸Laboratory of Statistical Immunology, Immunology Frontier Research Center 962 (WPI-IFReC), Osaka University, Suita, Japan. 963 ⁹Department of Neurology, Massachusetts General Hospital, Harvard Medical 964 965 School, Boston, MA, USA ¹⁰Laboratory of Experimental Cardiology, Division of Heart and Lungs, University 966 Medical Center Utrecht, University of Utrecht, Utrecht, Netherlands 967 ¹¹deCODE genetics/AMGEN inc, Reykjavik, Iceland 968 ¹²Center for Genomic Medicine, Massachusetts General Hospital (MGH), Boston, 969 970 MA, USA 971 ¹³J. Philip Kistler Stroke Research Center, Department of Neurology, MGH, 972 Boston, MA, USA ¹⁴Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, 973

- 974 USA
- 975 ¹⁵Population Health Research Institute, McMaster University, Hamilton, Canada

- 976 ¹⁶Department of Epidemiology, Erasmus University Medical Center, Rotterdam,
- 977 Netherlands
- ¹⁷Department of Radiology and Nuclear Medicine, Erasmus University Medical
 Center, Rotterdam, Netherlands
- 980 ¹⁸Department of Medicine and Clinical Science, Graduate School of Medical
- 981 Sciences, Kyushu University, Fukuoka, Japan
- 982 ¹⁹Department of Clinical Sciences, Lund University, Malmö, Sweden
- 983 ²⁰Univ. Lille, Inserm, Institut Pasteur de Lille, LabEx DISTALZ-UMR1167, Risk
- 984 factors and molecular determinants of aging-related diseases, F-59000 Lille,
 985 France
- ²¹Centre Hosp. Univ Lille, Epidemiology and Public Health Department, F-59000
 Lille, France
- 988 ²²AA Martinos Center for Biomedical Imaging, Department of Radiology,
- 989 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
- 990 ²³Cardiovascular Health Research Unit, Departments of Biostatistics and Medicine,
- 991 University of Washington, Seattle, WA, USA
- 992 ²⁴Division of Neurology, Faculty of Medicine, Brain Research Center, University
- 993 of British Columbia, Vancouver, Canada
- 994 ²⁵School of Life Science, University of Lincoln, Lincoln, UK
- 995 ²⁶Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto
- 996 Neurologico "Carlo Besta", Milano, Italy
- 997 ²⁷Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA
- ²⁸MRC/BHF Cardiovascular Epidemiology Unit, Department of Public Health and
 Primary Care, University of Cambridge, Cambridge, UK
- ²⁹The National Institute for Health Research Blood and Transplant Research Unit
- 1001 in Donor Health and Genomics, University of Cambridge, UK
- ³⁰Neurovascular Research Laboratory, Vall d'Hebron Institut of Research,
- 1003 Neurology and Medicine Departments-Universitat Autònoma de Barcelona, Vall
- 1004 d'Hebrón Hospital, Barcelona, Spain
- 1005 ³¹Stroke Pharmacogenomics and Genetics, Fundacio Docència i Recerca
- 1006 MutuaTerrassa, Terrassa, Spain
- ³²Children's Research Institute, Children's National Medical Center, Washington,
 DC, USA
- ³³Center for Translational Science, George Washington University, Washington,
 DC, USA
- ³⁴Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA,
 USA
- 1013 ³⁵Harvard Medical School, Boston, MA, USA
- 1014 ³⁶Center for Public Health Genomics, Department of Public Health Sciences,
- 1015 University of Virginia, Charlottesville, VA, USA
- ³⁷Department of Neurology, University of Maryland School of Medicine and
- 1017 Baltimore VAMC, Baltimore, MD, USA
- 1018 ³⁸Departments of Medicine, Pediatrics and Population Health Science, University
- 1019 of Mississippi Medical Center, Jackson, MS, USA
- ³⁹Institute of Cardiovascular Research, Royal Holloway University of London,
- 1021 UK & Ashford and St Peters Hospital, Surrey UK
- ⁴⁰Department of Psychiatry, The Hope Center Program on Protein Aggregation and
- 1023 Neurodegeneration (HPAN), Washington University, School of Medicine, St. Louis,
- 1024 MO, USA

- ⁴¹Department of Developmental Biology, Washington University School of
- 1026 Medicine, St. Louis, MO, USA
- ⁴²NIHR Blood and Transplant Research Unit in Donor Health and Genomics,
- 1028 Department of Public Health and Primary Care, University of Cambridge,
 1029 Cambridge, UK
- 1029 Cambridge, UK
- 1030 ⁴³Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus,
- 1031 Hinxton, Cambridge, UK
- ⁴⁴British Heart Foundation, Cambridge Centre of Excellence, Department of
- 1033 Medicine, University of Cambridge, Cambridge, UK
- ⁴⁵Department of Medical Genetics, University Medical Center Utrecht, Utrecht,
 Netherlands
- ⁴⁶Department of Epidemiology, Julius Center for Health Sciences and Primary
- 1037 Care, University Medical Center Utrecht, Utrecht, Netherlands
- 1038 ⁴⁷Boston University School of Public Health, Boston, MA, USA
- 1039 ⁴⁸Framingham Heart Study, Framingham, MA, USA
- ⁴⁹Department of Immunology, Genetics and Pathology and Science for Life
- 1041 Laboratory, Uppsala University, Uppsala, Sweden
- ⁵⁰Department of Genetics, University of North Carolina, Chapel Hill, NC, USA
- ⁵¹Department of Neurology and Stroke Center, Basel University Hospital,
 Switzerland
- ⁵²Neurorehabilitation Unit, University and University Center for Medicine of
- 1046 Aging and Rehabilitation Basel, Felix Platter Hospital, Basel, Switzerland
- ⁵³Department of Neurology, Yale University School of Medicine, New Haven, CT,
 USA
- ⁵⁴Program in Medical and Population Genetics, The Broad Institute of Harvard and
 MIT, Cambridge, MA, USA
- 1051 ⁵⁵Department of Neurology, Johns Hopkins University School of Medicine,
- 1052 Baltimore, MD, USA
- 1053 ⁵⁶Neuroscience Institute, SF Medical Center, Trenton, NJ, USA
- ⁵⁷Icelandic Heart Association Research Institute, Kopavogur, Iceland
- 1055 ⁵⁸University of Iceland, Faculty of Medicine, Reykjavik, Iceland
- ⁵⁹Department of Medical Sciences, Molecular Epidemiology and Science for Life
- 1057 Laboratory, Uppsala University, Uppsala, Sweden
- ⁶⁰Division of Public Health Sciences, Fred Hutchinson Cancer Research Center,
 Seattle, WA, USA
- ⁶¹Laboratory of Epidemiology and Population Science, National Institute on Aging,
 National Institutes of Health, Bethesda, MD, USA
- ⁶²Department of Neurology, Leeds General Infirmary, Leeds Teaching Hospitals
- 1063 NHS Trust, Leeds, UK
- ⁶³National Institute for Health and Welfare, Helsinki, Finland
- 1065 ⁶⁴FIMM Institute for Molecular Medicine Finland, Helsinki, Finland
- ⁶⁵Department of Epidemiology, University of Washington, Seattle, WA, USA
- 1067 ⁶⁶Public Health Stream, Hunter Medical Research Institute, New Lambton,
- 1068 Australia
- ⁶⁷Faculty of Health and Medicine, University of Newcastle, Newcastle, Australia
- ⁶⁸School of Public Health, University of Alabama at Birmingham, Birmingham, AL,
 USA
- ⁶⁹Department of Biostatistical Sciences, Wake Forest School of Medicine,
- 1073 Winston-Salem, NC, USA

- ⁷⁰Aflac Cancer and Blood Disorder Center, Department of Pediatrics, Emory
- 1075 University School of Medicine, Atlanta, GA, USA
- ⁷¹Department of Medicine, Division of Cardiovascular Medicine, Stanford
- 1077 University School of Medicine, CA, USA
- ⁷²Department of Medical Sciences, Molecular Epidemiology and Science for Life
 Laboratory, Uppsala University, Uppsala, Sweden
- ⁷³Epidemiology, School of Public Health, University of Alabama at Birmingham,
 USA
- ⁷⁴Brown Foundation Institute of Molecular Medicine, University of Texas Health
 Science Center at Houston, Houston, TX, USA
- ⁷⁵Neurovascular Research Group (NEUVAS), Neurology Department, Institut
- 1085 Hospital del Mar d'Investigació Mèdica, Universitat Autònoma de Barcelona,
 1086 Barcelona, Spain
- ⁷⁶Department of Pharmacotherapy and Translational Research and Center for
- 1088 Pharmacogenomics, University of Florida, College of Pharmacy, Gainesville, FL,1089 USA
- ⁷⁷Division of Cardiovascular Medicine, College of Medicine, University of Florida,
 Gainesville, FL, USA
- ⁷⁸Department of Cardiology, Leiden University Medical Center, Leiden, the
 Netherlands
- ⁷⁹Program in Bioinformatics and Integrative Genomics, Harvard Medical School,
 Boston, MA, USA
- ⁸⁰Department of Biology, East Carolina University, Greenville, NC, USA
- ⁸¹Center for Health Disparities, East Carolina University, Greenville, NC, USA
- 1098 ⁸²University of Cincinnati College of Medicine, Cincinnati, OH, USA
- 1099 ⁸³RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
- ⁸⁴Department of Medicine, University of Colorado Denver, Anschutz Medical
- 1101 Campus, Aurora, CO, USA
- ⁸⁵Center for Public Health Genomics and Department of Biostatistical Sciences,
- 1103 Wake Forest School of Medicine, Winston-Salem, NC, USA
- ⁸⁶MRC Epidemiology Unit, University of Cambridge School of Clinical Medicine,
- 1105 Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK
- ⁸⁷Intramural Research Program, National Institute on Aging, National Institutes of
 Health, Bethesda, MD, USA
- ⁸⁸Department of Neurology, Radiology, and Biomedical Engineering, Washington
- 1109 University School of Medicine, St. Louis, MO, USA
- 1110 ⁸⁹KU Leuven University of Leuven, Department of
- 1111 Neurosciences, Experimental Neurology, Leuven, Belgium
- ⁹⁰VIB Center for Brain & Disease Research, University Hospitals Leuven,
- 1113 Department of Neurology, Leuven, Belgium
- ⁹¹Univ.-Lille, INSERM U 1171. CHU Lille. Lille, France
- ⁹²Department of Medical and Molecular Genetics, King's College London, London,
 UK
- ⁹³SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King's
- 1118 College London, London, UK
- ⁹⁴Northern Institute for Cancer Research, Paul O'Gorman Building, Newcastle
- 1120 University, Newcastle, UK
- ⁹⁵Department of Clinical Sciences Lund, Neurology, Lund University, Lund,
- 1122 Sweden

- ⁹⁶Department of Neurology and Rehabilitation Medicine, Skåne University
- 1124 Hospital, Lund, Sweden
- ⁹⁷Bioinformatics Core Facility, University of Gothenburg, Gothenburg, Sweden
- ⁹⁸Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
 Stockholm, Sweden
- ⁹⁹University of Technology Sydney, Faculty of Health, Ultimo, Australia
- ¹⁰⁰Department of Medicine, University of Maryland School of Medicine, MD, USA
- ¹⁰¹Department of Neurology, Mayo Clinic, Jacksonville, FL, USA
- ¹⁰²Geriatrics Research and Education Clinical Center, Baltimore Veterans
- 1132 Administration Medical Center, Baltimore, MD, USA
- ¹⁰³Division of Geriatrics, School of Medicine, University of Mississippi Medical
- 1134 Center, Jackson, MS, USA
- ¹⁰⁴Memory Impairment and Neurodegenerative Dementia Center, University of
 Mississippi Medical Center, Jackson, MS, USA
- ¹⁰⁵Laboratory of Neurogenetics, National Institute on Aging, National institutes of
 Health, Bethesda, MD, USA
- ¹⁰⁶Data Tecnica International, Glen Echo MD, USA
- ¹⁰⁷Department of Epidemiology and Public Health, Graduate School of Medical
- 1141 Sciences, Kyushu University, Fukuoka, Japan
- ¹⁰⁸Clinical Research Facility, Department of Medicine, NUI Galway, Galway,
 Ireland
- ¹⁰⁹Cardiovascular Health Research Unit, Department of Medicine, University of
 Washington, Seattle, WA, USA
- ¹¹⁰Department of Epidemiology, University of Washington, Seattle, WA, USA
- ¹¹¹Department of Health Services, University of Washington, Seattle, WA, USA
- ¹¹²Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA
- 1149 ¹¹³Brain Center Rudolf Magnus, Department of Neurology, University Medical
- 1150 Center Utrecht, Utrecht, The Netherlands
- ¹¹⁴Usher Institute of Population Health Sciences and Informatics, University of
 Edinburgh, Edinburgh, UK
- ¹¹⁵Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
- ¹¹⁶Fred Hutchinson Cancer Research Center, University of Washington, Seattle,
 WA, USA
- ¹¹⁷Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA
- ¹¹⁸Department of Biostatistics, University of Washington, Seattle, WA, USA
- ¹¹⁹Nuffield Department of Clinical Neurosciences, University of Oxford, UK
- ¹²⁰Institute for Translational Genomics and Population Sciences, Los Angeles
- Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA,
 USA
- ¹²¹Division of Genomic Outcomes, Department of Pediatrics, Harbor-UCLA
- 1163 Medical Center, Torrance, CA, USA
- ¹²²Department of Neurology, Miller School of Medicine, University of Miami,
- 1165 Miami, FL, USA
- ¹²³Department of Allergy and Rheumatology, Graduate School of Medicine, the
 University of Tokyo, Tokyo, Japan
- ¹²⁴Center for Public Health Genomics, University of Virginia, Charlottesville, VA,
 USA
- ¹²⁵Department of Pediatrics, College of Medicine, University of Oklahoma Health
- 1171 Sciences Center, Oklahoma City, OK, USA
- ¹²⁶Department of Neurology, Medical University of Graz, Graz, Austria

- ¹²⁷University Medicine Greifswald, Institute for Community Medicine, SHIP-KEF,
- 1174 Greifswald, Germany
- ¹²⁸University Medicine Greifswald, Department of Neurology, Greifswald,
- 1176 Germany
- ¹²⁹Department of Neurology, Jagiellonian University, Krakow, Poland
- ¹³⁰Department of Neurology, Justus Liebig University, Giessen, Germany
- ¹³¹Department of Clinical Neurosciences/Neurology, Institute of Neuroscience and
- 1180 Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg,
- 1181 Sweden
- 1182 ¹³²Sahlgrenska University Hospital, Gothenburg, Sweden
- ¹³³Stroke Division, Florey Institute of Neuroscience and Mental Health, University
- 1184 of Melbourne, Heidelberg, Australia
- 1185 ¹³⁴Austin Health, Department of Neurology, Heidelberg, Australia
- ¹³⁵Department of Internal Medicine, Section Gerontology and Geriatrics, Leiden
- 1187 University Medical Center, Leiden, the Netherlands
- 1188 ¹³⁶INSERM U1219, Bordeaux, France
- 1189 ¹³⁷Department of Public Health, Bordeaux University Hospital, Bordeaux, France
- ¹³⁸Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University
- 1191 Medical Center Rotterdam, Netherlands
- ¹³⁹Center for Medical Systems Biology, Leiden, Netherlands
- ¹⁴⁰School of Medicine, Dentistry and Nursing at the University of Glasgow,
- 1194 Glasgow, UK
- ¹⁴¹Department of Epidemiology and Population Health, Albert Einstein College of
 Medicine, NY, USA
- ¹⁴²Department of Physiology and Biophysics, University of Mississippi Medical
- 1198 Center, Jackson, MS, USA
- ¹⁴³A full list of members and affiliations appears in the Supplementary Note
- 1200 ¹⁴⁴Department of Human Genetics, McGill University, Montreal, Canada
- ¹⁴⁵Department of Pathophysiology, Institute of Biomedicine and Translation
 Medicine, University of Tartu, Tartu, Estonia
- 1203 ¹⁴⁶Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia
- 1204 ¹⁴⁷Clinical Gene Networks AB, Stockholm, Sweden
- 1205 ¹⁴⁸Department of Genetics and Genomic Sciences, The Icahn Institute for
- 1206 Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai, New1207 York, NY, USA
- 1208 ¹⁴⁹Department of Pathophysiology, Institute of Biomedicine and Translation
- 1209 Medicine, University of Tartu, Biomeedikum, Tartu, Estonia
- 1210 ¹⁵⁰Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska
- 1211 Institutet, Karolinska Universitetssjukhuset, Huddinge, Sweden.
- 1212 ¹⁵¹Clinical Gene Networks AB, Stockholm, Sweden
- 1213 ¹⁵²Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Team
- 1214 Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France
- 1215 ¹⁵³ICAN Institute for Cardiometabolism and Nutrition, Paris, France
- ¹⁵⁴Department of Biomedical Engineering, University of Virginia, Charlottesville,
 VA, USA
- 1218 ¹⁵⁵Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA
- 1219 ¹⁵⁶Seattle Epidemiologic Research and Information Center, VA Office of Research 1220 and Development, Seattle, WA, USA
- 1221 ¹⁵⁷Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA,
- 1222 USA

- ¹⁵⁸Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, 1223 1224 Gjettum, Norway ¹⁵⁹Saw Swee Hock School of Public Health, National University of Singapore and 1225 National University Health System, Singapore 1226 ¹⁶⁰National Heart and Lung Institute, Imperial College London, London, UK 1227 ¹⁶¹Department of Gene Diagnostics and Therapeutics, Research Institute, National 1228 1229 Center for Global Health and Medicine, Tokyo, Japan ¹⁶²Department of Epidemiology, Tulane University School of Public Health and 1230 1231 Tropical Medicine, New Orleans, LA, USA ¹⁶³Department of Cardiology, University Medical Center Groningen, University of 1232 1233 Groningen, Netherlands ¹⁶⁴MRC-PHE Centre for Environment and Health, School of Public Health, 1234 1235 Department of Epidemiology and Biostatistics, Imperial College London, London, 1236 UK ¹⁶⁵Department of Epidemiology and Biostatistics, Imperial College London, 1237 1238 London, UK ¹⁶⁶Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK 1239 ¹⁶⁷National Heart, Lung and Blood Research Institute, Division of Intramural 1240 Research, Population Sciences Branch, Framingham, MA, USA 1241 1242 ¹⁶⁸A full list of members and affiliations appears at the end of the manuscript 1243 ¹⁶⁹Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA 1244 1245 ¹⁷⁰Oklahoma Center for Neuroscience, Oklahoma City, OK, USA ¹⁷¹Department of Pathology and Genetics, Institute of Biomedicine, The 1246 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 1247 ¹⁷²Department of Neurology, Helsinki University Hospital, Helsinki, Finland 1248 ¹⁷³Clinical Neurosciences, Neurology, University of Helsinki, Helsinki, Finland 1249 ¹⁷⁴Department of Neurology, University of Washington, Seattle, WA, USA 1250 ¹⁷⁵Albrecht Kossel Institute, University Clinic of Rostock, Rostock, Germany 1251 ¹⁷⁶Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield 1252 Department of Population Health, University of Oxford, Oxford, UK 1253 ¹⁷⁷Department of Genetics, Perelman School of Medicine, University of 1254 1255 Pennsylvania, PA, USA ¹⁷⁸Faculty of Medicine, University of Iceland, Reykjavik, Iceland 1256 ¹⁷⁹Departments of Neurology and Public Health Sciences, University of Virginia 1257 1258 School of Medicine, Charlottesville, VA, USA ¹⁸⁰Department of Neurology, Boston University School of Medicine, Boston, MA, 1259 1260 USA ¹⁸¹Human Genetics Center, University of Texas Health Science Center at Houston, 1261 Houston, TX, USA 1262 ¹⁸²Center for Genomic Medicine, Kyoto University Graduate School of Medicine, 1263 1264 Kyoto, Japan ¹⁸³Munich Cluster for Systems Neurology (SyNergy), Munich, Germany 1265 ¹⁸⁴German Center for Neurodegenerative Diseases (DZNE), Munich, Germany 1266 ¹⁸⁵Boston University School of Medicine, Boston, MA, USA 1267 ¹⁸⁶University of Kentucky College of Public Health, Lexington, KY, USA 1268 ¹⁸⁷University of Newcastle and Hunter Medical Research Institute, New Lambton, 1269 1270 Australia ¹⁸⁸Univ. Montpellier, Inserm, U1061, Montpellier, France 1271
- ¹⁸⁹Centre for Research in Environmental Epidemiology, Barcelona, Spain

- ¹⁹⁰Department of Neurology, Università degli Studi di Perugia, Umbria, Italy
- ¹⁹¹Department of Medicine, University of Maryland School of Medicine, Baltimore,
 MD, USA
- 1276 ¹⁹²Broad Institute, Cambridge, MA, USA
- ¹⁹³Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, UMR
- 1278 1219, Bordeaux, France
- 1279 ¹⁹⁴Bordeaux University Hospital, Department of Neurology, Memory Clinic,
- 1280 Bordeaux, France
- ¹⁹⁵Neurovascular Research Laboratory. Vall d'Hebron Institut of Research,
- 1282 Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall
- 1283 d'Hebrón Hospital, Barcelona, Spain
- 1284 ¹⁹⁶University Medicine Greifswald, Department of Internal Medicine B,
- 1285 Greifswald, Germany
- 1286 ¹⁹⁷DZHK, Greifswald, Germany
- ¹⁹⁸Robertson Center for Biostatistics, University of Glasgow, Glasgow, UK
- 1288 ¹⁹⁹Hero DMC Heart Institute, Dayanand Medical College & Hospital, Ludhiana,
- 1289 India
- 1290 ²⁰⁰Atherosclerosis Research Unit, Department of Medicine Solna, Karolinska
- 1291 Institutet, Stockholm, Sweden
- 1292 ²⁰¹Karolinska Institutet, Stockholm, Sweden
- ²⁰²Division of Emergency Medicine, and Department of Neurology, Washington
- 1294 University School of Medicine, St. Louis, MO, USA
- 1295 ²⁰³Tohoku Medical Megabank Organization, Sendai, Japan
- ²⁰⁴Department of Psychiatry, Washington University School of Medicine, St. Louis,
 MO, USA
- ²⁰⁵Department of Public Health and Caring Sciences / Geriatrics, Uppsala
- 1299 University, Uppsala, Sweden
- 1300 ²⁰⁶Epidemiology and Prevention Group, Center for Public Health Sciences,
- 1301 National Cancer Center, Tokyo, Japan
- ²⁰⁷Department of Internal Medicine and the Center for Clinical and Translational
- 1303 Science, The Ohio State University, Columbus, OH, USA
- 1304 ²⁰⁸Institute of Neuroscience and Physiology, the Sahlgrenska Academy at
- 1305 University of Gothenburg, Goteborg, Sweden
- ²⁰⁹Department of Basic and Clinical Neurosciences, King's College London,
 London, UK
- ²¹⁰Department of Health Care Administration and Management, Graduate School
 of Medical Sciences, Kyushu University, Japan
- 1310 ²¹¹Department of Medicine and Clinical Science, Graduate School of Medical
- 1311 Sciences, Kyushu University, Japan
- 1312 ²¹²Landspitali National University Hospital, Departments of Neurology &
- 1313 Radiology, Reykjavik, Iceland
- 1314 ²¹³Department of Neurology, Heidelberg University Hospital, Germany
- 1315 ²¹⁴Department of Neurology, Erasmus University Medical Center
- 1316 ²¹⁵Hospital Universitari Mutua Terrassa, Terrassa (Barcelona), Spain
- ²¹⁶Albert Einstein College of Medicine, Montefiore Medical Center, New York,
 NY, USA
- 1319 ²¹⁷John Hunter Hospital, Hunter Medical Research Institute and University of
- 1320 Newcastle, Newcastle, NSW, Australia
- 1321 ²¹⁸Centre for Prevention of Stroke and Dementia, Nuffield Department of Clinical
- 1322 Neurosciences, University of Oxford, UK

- 1323 ²¹⁹Department of Medical Sciences, Uppsala University, Uppsala, Sweden
- 1324 ²²⁰Genetic and Genomic Epidemiology Unit, Wellcome Trust Centre for Human
 1325 Genetics, University of Oxford, Oxford, UK
- 1326 ²²¹The Wellcome Trust Centre for Human Genetics, Oxford, UK
- 1327 ²²²Beth Israel Deaconess Medical Center, Boston, MA, USA
- 1328 ²²³Wake Forest School of Medicine, Wake Forest, NC, USA
- 1329 ²²⁴Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
- 1330 ²²⁵BioBank Japan, Laboratory of Clinical Sequencing, Department of
- 1331 Computational biology and medical Sciences, Graduate school of Frontier Sciences,
- 1332 The University of Tokyo, Tokyo, Japan
- 1333 ²²⁶Neurovascular Research Laboratory, Vall d'Hebron Institut of Research,
- 1334 Neurology and Medicine Departments-Universitat Autònoma de Barcelona. Vall
- 1335 d'Hebrón Hospital, Barcelona, Spain
- 1336 ²²⁷Department of Biostatistics, University of Liverpool, Liverpool, UK
- 1337 ²²⁸Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
- 1338 ²²⁹Institute of Genetic Epidemiology, Helmholtz Zentrum München German
- 1339 Research Center for Environmental Health, Neuherberg, Germany
- 1340 ²³⁰Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany
- ²³¹DZHK (German Centre for Cardiovascular Research), partner site Munich Heart
 Alliance, Munich, Germany
- 1343 ²³²Department of Cerebrovascular Diseases, Fondazione IRCCS Istituto
- 1344 Neurologico "Carlo Besta", Milano, Italy
- 1345 ²³³Karolinska Institutet, MEB, Stockholm, Sweden
- 1346 ²³⁴University of Tartu, Estonian Genome Center, Tartu, Estonia, Tartu, Estonia
- ²³⁵Department of Clinical and Experimental Sciences, Neurology Clinic,
- 1348 University of Brescia, Italy
- 1349 ²³⁶Translational Genomics Unit, Department of Oncology, IRCCS Istituto di
- 1350 Ricerche Farmacologiche Mario Negri, Milano, Italy
- ²³⁷Department of Genetics, Microbiology and Statistics, University of Barcelona,
 Barcelona, Spain
- 1353 ²³⁸Psychiatric Genetics Unit, Group of Psychiatry, Mental Health and Addictions,
- 1354 Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona,
- Biomedical Network Research Centre on Mental Health (CIBERSAM), Barcelona,Spain
- ²³⁹Department of Neurology, IMIM-Hospital del Mar, and Universitat Autònoma
 de Barcelona, Spain
- 1359 ²⁴⁰IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- 1360 ²⁴¹National Institute for Health Research Comprehensive Biomedical Research
- 1361 Centre, Guy's & St. Thomas' NHS Foundation Trust and King's College London,
- 1362 London, UK
- ²⁴²Division of Health and Social Care Research, King's College London, London,
 UK
- 1365 ²⁴³FIMM-Institute for Molecular Medicine Finland, Helsinki, Finland
- 1366 ²⁴⁴THL-National Institute for Health and Welfare, Helsinki, Finland
- ²⁴⁵Iwate Tohoku Medical Megabank Organization, Iwate Medical University, Iwate,
 Japan
- ²⁴⁶BHF Glasgow Cardiovascular Research Centre, Faculty of Medicine, Glasgow,
 UK
- 1371 ²⁴⁷deCODE Genetics/Amgen, Inc., Reykjavik, Iceland
- 1372 ²⁴⁸Icelandic Heart Association, Reykjavik, Iceland

- 1373 ²⁴⁹Institute of Biomedicine, the Sahlgrenska Academy at University of Gothenburg,
- 1374 Goteborg, Sweden
- 1375 ²⁵⁰Department of Epidemiology, University of Maryland School of Medicine,
- 1376 Baltimore, MD, USA
- 1377 ²⁵¹Institute of Cardiovascular and Medical Sciences, Faculty of Medicine,
- 1378 University of Glasgow, Glasgow, UK
- 1379 ²⁵²Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich,
- 1380 Germany
- 1381 ²⁵³Division of Epidemiology and Prevention, Aichi Cancer Center Research
- 1382 Institute, Nagoya, Japan
- ²⁵⁴Department of Epidemiology, Nagoya University Graduate School of Medicine,
 Nagoya, Japan
- ²⁵⁵University Medicine Greifswald, Institute for Community Medicine, SHIP-KEF,
 Greifswald, Germany
- 1387 ²⁵⁶Department of Neurology, Caen University Hospital, Caen, France
- 1388 ²⁵⁷University of Caen Normandy, Caen, France
- 1389 ²⁵⁸Department of Internal Medicine, Erasmus University Medical Center,
- 1390 Rotterdam, Netherlands
- 1391 ²⁵⁹Landspitali University Hospital, Reykjavik, Iceland
- 1392 ²⁶⁰Survey Research Center, University of Michigan, Ann Arbor, MI, USA
- 1393 ²⁶¹University of Virginia Department of Neurology, Charlottesville, VA, USA
- 1394
- 1395